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ABSTRACT 
Previously identified cerebrospinal fluid (CSF) biomarkers were studied in 37 twins with 
schizophrenia or bipolar disorder to determine their genetic and environmental properties. 
Further, comorbidities and sibling risks were investigated in patients with schizophrenia 
(n=22,781), bipolar disorder (n=30,761) and depression (n=172,479) in relation to multiple 
sclerosis (MS) (n=16,467) in a nationwide cohort 
In Study I, CSF was analyzed using scanning electron microscopy in twins with 
schizophrenia and bipolar disorder to identify microscopic structures that had previously 
been established in patients with schizophrenia and bipolar disorder. Microscopic structures 
were found not only in the patients but also in the non-affected twin siblings to a higher 
degree than in healthy controls. The results indicate that genetic and shared environmental 
mechanisms might be involved in the development of CSF structures. 
Study II was a case series in which microparticles were studied in the CSF of healthy 
controls and in patients with schizophrenia. Microparticles may be indicative of stress-
induced cell activation. In the patients with schizophrenia microparticles that originated 
from leukocyte and endothelial cells were accumulated in higher levels as compared with 
the healthy controls. 
In Study III, immune and amyloid biomarkers previously associated with psychotic 
disorders were analyzed in the CSF of twins. Soluble cluster of differentiation 14 (sCD14), 
a protein expressed by microglia in the central nervous system, was found to highly 
correlate within monozygotic twins. In the co-twin control analysis higher levels were 
observed in patients with schizophrenia and bipolar disorder compared with the non-
affected co-twins. sCD14 was also associated with negative psychotic symptoms and 
schizotypal and paranoid personality traits. The results strengthen previous findings of 
microglia activation in psychotic disorders. 
In Study IV, tryptophan metabolites and cytokines were analyzed in twins with 
schizophrenia and bipolar disorder. None of the substances correlated within the 
monozygotic twin pairs, which indicates the influence of environmental factors. Kynurenic 
and quinolinic acid were shown to be associated with schizotypal personality traits, 
strengthening previous results of an association between the tryptophan metabolites and 
psychosis. 
In Study V, comorbidity between the neuroinflammatory disorder MS and schizophrenia, 
bipolar disorder and depression was analyzed in a nationwide cohort. Consistent with 
previous studies an increased MS risk was noted in patients with bipolar disorder and 
depression. An increased MS risk was also found in males with a diagnosis of bipolar 
disorder and previous manic episodes. Decreased MS risk was seen in patients with 
schizophrenia. No change in MS risk was detected in the siblings to patients with 
schizophrenia, bipolar disorder and depression. Possible inflammatory mechanisms may 
account for the comorbidity between affective disorders and MS, whereas the protective 
effect of schizophrenia on MS risk remains to be further investigated. 
Biomarker analysis in CSF using twin methodology revealed some promising findings for 
future biomarker studies. However, larger twin cohorts are desirable for conclusive 
confirmation. The potential mechanisms underlying the associations between MS and 
psychiatric disorders require further study. 
  
  
 
SAMMANFATTNING 
Schizofreni och bipolär sjukdom är psykiska sjukdomar som antas drabba hjärnan. De 
bakomliggande orsakerna är till stor del okända. Ärftliga faktorer är av betydelse, men det 
saknas kunskap om vad som mer specifikt händer i hjärnan när sjukdomarna uppstår. 
Schizofreni och bipolär sjukdom tycks delvis ha en gemensam ärftlig grund och vissa 
symtom överlappar. Det finns inga objektiva sätt att diagnostisera psykiska sjukdomar idag, 
vilket kan göra att diagnosen inte ställs i tid och att behandlingen fördröjs. Ett sätt att förbättra 
diagnostiken är att identifiera biomarkörer. Exempel på biomarkörer kan vara resultatet från 
ett blodprov, en röntgenundersökning eller en psykologisk testning. 
Syftet med denna avhandling har varit att undersöka potentiella biomarkörer för schizofreni 
och bipolär sjukdom genom att analysera ryggmärgsvätska som omger hjärnan och 
ryggmärgen. Vätskan fungerar bland annat som en stötdämpare för hjärnan och som 
transportör av vissa substanser och kan utvinnas genom att ett ryggvätskeprov tas med hjälp 
av en nål. 
I forskningen om biomarkörer brukar man först jämföra nivåerna av en specifik markör 
mellan friska och sjuka individer. Om markören skiljer sig kan man gå vidare för att ta reda 
på om skillnaden beror på ärftliga eller miljöfaktorer (delade eller unika) genom att analysera 
tvillingpar. I avhandlingens första studier (I-IV) analyserades biomarkörer i ryggmärgsvätska 
från tvillingar med schizofreni eller bipolär sjukdom (totalt 37 individer från 18 kompletta 
tvillingpar). I den sista studien (V) analyserades samsjukligheten mellan psykisk sjukdom och 
den neurologiska sjukdomen multipel skleros. Tidigare studier har nämligen visat på en ökad 
risk för bipolär sjukdom, depression och psykos vid multipel skleros, vilket skulle kunna bero 
på nedärvda faktorer. 
I Studie I analyserades ryggmärgsvätska med svepelektronmikroskop för att identifiera 
mikrometer-stora strukturer i ryggmärgsvätska hos tvillingar med schizofreni eller bipolär 
sjukdom. Den mikroskopiska undersökningen visade att tvillingarna med schizofreni eller 
bipolär sjukdom hade cirkulära strukturer i storleken 0,5-1 mikrometer i ryggmärgsvätskan i 
betydligt större utsträckning än när de jämfördes med friska kontrollindivider. Även de friska 
tvillingarna med ett sjukt syskon, som således hade en ökad ärftlighet för sjukdomen, 
uppvisade en ökad mängd strukturer. Resultaten kan tolkas som att strukturerna orsakas av 
ärftliga faktorer, men också av miljöfaktorer som delas inom ett tvillingpar. 
Studie II är en fallrapport där mikropartiklar analyserades i ryggmärgsvätskan hos ett 
tvillingpar med schizofreni och jämfördes med friska kontrollpersoner. Mikropartiklar är små 
fragment av celler som frigörs från modercellen med syftet att sända ut signaler till sin 
omgivning och en hypotes är att mikropartiklarna utsöndras vid stress. Fallstudien visade att 
mängden mikropartiklar som utsöndrades från tvillingarna med schizofreni var betydligt 
högre jämfört med kontroller. Mikropartiklarna som med hjälp av antikroppar kunde spåras 
till vita blodkroppar och celler från kärlväggar var klart förhöjda, medan mängden 
mikropartiklar från blodplättar inte skilde sig från kontrollerna. Det var första gången en ökad 
mängd mikropartiklar kunde påvisas hos patienter med schizofreni. 
I Studie III analyserades biomarkörer för immunologisk aktivitet i ryggmärgsvätskan hos 
tvillingarna. Flera av biomarkörerna hade tidigare visat sig vara förändrade vid schizofreni 
och bipolär sjukdom. Undersökningen visade intressanta resultat för lösligt CD14 som i 
nervsystemet tillverkas av celltypen mikroglia som i sin tur är en viktig del av 
immunförsvaret i hjärnan. Man fann att nivåerna av lösligt CD14 överensstämde ovanligt 
mycket mellan enäggstvillingar (som är 100% genetiskt lika), vilket tyder på hög ärftlig 
styrning av dess produktion. Likväl visade analysen mellan tvillingparen att 
sjukdomsspecifika faktorer i kombination med ärftliga faktorer (orsakade av schizofreni eller 
  
 
bipolär sjukdom) gav ökade nivåer av lösligt CD14. Resultaten kan tolkas som att mikroglia-
cellerna är aktiverade vid schizofreni och bipolär sjukdom. 
I Studie IV undersöktes tvillingarnas ryggmärgsvätskenivåer av tryptofan och dess 
nedbrytningsprodukter samt cytokiner. Tryptofan är en aminosyra som bland annat 
omvandlas till serotonin som är vital för vårt välbefinnande. Tryptofan bryts också ner via 
kynurensyra-systemet som bland annat påverkar glutamat- och dopamin-nivåerna. Glutamat 
och dopamin har sannolikt en stor av betydelse för uppkomsten och utvecklingen av 
psykotiska symtom. Studien visade att tryptofan-metaboliterna kynurensyra och quinolinsyra 
var associerade till ökade psykossymtom hos patienterna. 
Studie V är en registerstudie med hela Sveriges befolkning som underlag där sambandet 
mellan schizofreni, bipolär sjukdom, depression och den neurologiska sjukdomen multipel 
skleros undersöktes. I studien fann man som förväntat att risken för multipel skleros var 
förhöjd vid bipolär sjukdom och depression. Något oväntat så var risken för multipel skleros 
minskad hos patienterna med schizofreni. Syskon till patienter med bipolär sjukdom, 
depression eller schizofreni undersöktes också, men de visade inte någon ökad eller minskad 
risk för multipel skleros jämfört med kontrollpersoner utan ärftlighet för psykisk sjukdom. 
Resultaten från denna avhandling visar att analyser av biomarkörer i ryggmärgsvätska hos 
tvillingar är av stort värde. Trots det mindre antalet tvillingar som har analyserats så är antalet 
insamlade prover av ryggmärgsvätska bland det största någonsin hos tvillingar med allvarlig 
psykisk sjukdom. Det är också av stort intresse att ta reda på orsaken till varför patienterna 
med schizofreni i viss utsträckning verkar vara skyddade mot multipel skleros. 
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1 INTRODUCTION 
1.1 PSYCHIATRIC RESEARCH – POSSIBILITIES AND CHALLENGES 
Psychiatry is a medical discipline treating patients with psychiatric disorders characterized by 
a suggested dysfunction of the central nervous system (CNS). However, there is a critical 
difference between psychiatry and most other medical disciplines. In psychiatry the diagnosis 
is based on observed behavior and the patient’s own description of the symptoms sometimes 
combined with results from assessment scales and neuropsychological function tests. In most 
other medical disciplines the clinicians have access to various laboratory tests and 
radiological techniques, to establish the correct diagnosis, in addition to the physical 
symptoms that the patient presents. 
In medicine objective biological measures (such as results from laboratory tests and 
radiological examinations) are called biological markers or biomarkers. Psychiatry has lagged 
behind other areas of medicine in the identification of biomarkers for clinical diagnosis and 
treatment. Instead, the foundation of the diagnostic nomenclature is the symptom criteria 
presented in the Diagnostic and Statistical Manual of Mental Disorders, (DSM) [1] and the 
International Classification of Diseases (ICD) by the World Health Organization [2]. The 
categorical classification system may be problematic because the psychiatric syndromes often 
display symptoms within a spectrum. Also, there are problems with validity and inter-rater 
reliability of today’s nomenclature which is not fully satisfactory for the clinician [3]. 
The difficulty in measuring the biological processes of psychiatric disorders in the brain of 
living humans makes the psychiatric research more complicated compared with other areas of 
clinical medical research. It is more difficult to understand underlying pathophysiological 
processes and the weaknesses in the psychiatric diagnostic system make it harder to divide 
the patients into relevant groups for analysis. Even large-scale genetic studies, including 
thousands of study participants, that have scanned the whole genome for potential genetic 
biomarkers have generated less results than expected; one explanation may be the inherent 
weaknesses of today’s diagnostic classification system. 
The research field of biomarkers is intense and biomarkers may be useful for different 
purposes (e.g., risk prediction, treatment response and as a diagnostic aid) [4]. To develop 
biomarkers for psychiatric disorders examples of methods used are brain imaging techniques 
and genetic or biochemical analysis of various substrates such as blood, saliva and skin 
samples. In this context the cerebrospinal fluid (CSF) that is encircling the brain and the 
spinal cord is a useful substrate not only as a potential source of biomarkers but also to study 
the pathophysiology of the brain [5]. 
Nevertheless, it is a time-consuming procedure to collect samples from individual patients 
and in certain situations it may not even be ethical. In epidemiology research it is possible to 
avoid interference with patients by taking advantage of already existing data from population 
registers. Disease patterns of various disorders in large populations may be analyzed and 
associations found may not only generate new hypotheses, but will also answer important 
questions about causation. 
This thesis will focus on biomarkers and the underlying pathophysiology of schizophrenia 
and bipolar disorder by analyzing CSF collected from a cohort of twins. By using twin pairs, 
it is possible to analyze the influence of hereditary factors as well as the effect of the shared 
and unique environment. Finally, in a nation-wide epidemiological study comorbidities and 
familiar influences between multiple sclerosis (MS) and schizophrenia, bipolar disorder and 
depression are analyzed using Swedish population registers. 
 - 2 - 
 
 
1.2 DISORDERS OF THE CENTRAL NERVOUS SYSTEM 
1.2.1 Schizophrenia and bipolar disorder 
Schizophrenia and bipolar disorders are both severe mental disorders with a prevalence of 
approximately 0.4% and 2.4%, respectively [6, 7]. Schizophrenia is characterized by 
psychotic symptoms such as hallucinations, delusions and abnormal thought processes as 
well as social withdrawal and cognitive impairment [1]. Typically, its onset occurs in early 
adult life but the impairment of cognitive skills seems to develop already at a premorbid level 
[8]. Bipolar disorder is an affective disorder presenting symptoms such as episodic mood 
swings from mania to depression and psychotic symptoms that often appear during severe 
periods of mania and depression [1]. 
Similar to schizophrenia, bipolar disorder has its onset in early adulthood. Bipolar disorder is 
separated into bipolar disorder type I, characterized by manic and depressive episodes, and 
bipolar disorder type II, defined by less pronounced episodes of elevated mood called 
hypomania and depressive episodes. Cognitive deficits are also present in bipolar disorder [9-
11], although milder compared with schizophrenia [12]. There are likely genetic differences 
in the cognitive deficits of schizophrenia and bipolar disorder: not-affected co-twins of 
schizophrenia patients performed worse in cognitive testing compared with not-affected 
bipolar co-twins whose results did not deviate from the control twins [13, 14]. 
Schizoaffective disorder is classified as a separate disorder characterized by psychotic 
symptoms (e.g., hallucinations and delusions) comparable to schizophrenia and mood 
instability as in bipolar disorder [1]. Therefore, schizoaffective-disorder has been suggested 
to be a phenotype in the spectrum between schizophrenia and bipolar disorder [15]. 
The etiology of schizophrenia and bipolar disorder is not fully understood but genes seem to 
play an important role and heritability has been estimated to approximately 60 % [16]. The 
risk for schizophrenia and bipolar disorder increases with greater kinship, being highest in 
identical twins. Further there is an increased overlapping risk as shown in the figure (Figure 
1). Genetic linkage studies have given fewer results than expected over the years, indicating 
that schizophrenia and bipolar disorder are not caused by genes with large effect sizes. The 
recent large scale genome-wide association studies (GWAS) have been more successful and 
several loci associated with the respective disorder have been identified. The effect sizes have 
been small, indicating that many genes in combination may cause the disorders [17]. The 
overlapping genetic risks of schizophrenia and bipolar disorder have been explored with 
GWAS in combined samples of schizophrenia and bipolar patients and common risk loci 
have been identified (e.g., CACNA1C coding for proteins involved in voltage gated calcium 
channel activity and ANK3 coding for ankyrin 3 with the function to connect membrane 
proteins to the spectrin-actin cytoskeleton) [18, 19]. The CACNA1C and ANK3 risk genes 
have also been linked to aberrant results on functional magnetic resonance imaging (fMRI) 
scans in patients with bipolar disorder and their relatives [20, 21]. 
Finally, without forgetting to mention the environmental risk factors with substantial 
influence on the risk for schizophrenia and bipolar disorder. Environmental risk factors for 
schizophrenia include obstetric risk factors such as low birth weight and hypoxia at birth, 
early life viral infections and winter birth [22]. Similar risk factors seem to affect bipolar 
disorder (e.g., winter birth and prematurity increase the risk) [23]. 
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Figure 1. The morbidity risk of schizophrenia and bipolar disorder (BP) and overlapping 
risks. Identical twins share 100% of their genes; fraternal twins, parent-child and siblings, 
on average, 50% of their genes; and half sibling 2%. a. Concordance rates in twins from 
McGue, 1991 [24]. b. Relative risks from Lichtenstein, 2009 [16]. c. Concordance rates from 
Edvardsen, 2008 [25]. 
 
1.2.2 Depression 
Major depressive disorder is characterized by low mood and loss of interest that may persist 
from weeks up to several months and even years. The disorder has an episodic course. Other 
symptoms include low self-esteem, feelings of guilt, low energy, worsened appetite and 
suicidal ideation. Severe forms may be accompanied by psychotic symptoms. [1, 3]. 
Depression may affect individuals once or several times during their lifetime and usually 
arises after puberty. Risk factors include heredity, negative life events, medical conditions, 
other psychiatric diagnosis and alcohol or substance abuse. The lifetime prevalence may vary 
from 8%-12% in most countries of the world and the heritability has been estimated to 37 % 
[26]. As with bipolar disorder and schizophrenia, it is likely that many genes with smaller 
effect sizes affect the depression risk and many GWAS studies have failed to detect any 
common risk genes [26, 27]. Only recently two risk loci on chromosome 10 were found in 
Chinese women with severe depression, indicating that today’s classification of depression 
may have contributed to the failure of detecting risk genes previously [28]. 
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1.2.3 Multiple sclerosis and psychiatric comorbidity 
MS has a lifetime prevalence of 0.2% [29]. It is a disease affecting the brain and the spinal 
cord that may lead to disability with detrimental effects on quality of life. The disease is 
characterized by neuroinflammation that is mainly driven by lymphatic cells leading to 
demyelination and axonal loss. It has a relapse and remitting course but over time it often 
turns into a chronic disease. Environmental risk factors include infections (for instance, 
Epstein-Barr virus) smoking and reduced exposure to ultra-violet light. The incidence 
increases with distance from the equator (northward as well as southward) [30]. MS is more 
common in females than in males and the heritability has been estimated to 0.64 [31, 32]. The 
diagnosis is based on the physical symptoms that the patient presents in combination with 
CSF- and radiological examination [30]. 
Charcot, a neurologist, first described pathological abnormalities in patients with MS in 1868. 
Some years later he went on to describe psychiatric symptoms in MS patients [33] and since 
then several studies have demonstrated increased rates of depression and bipolar disorder in 
patients with MS [34-45].Associations have also been found between MS, schizophrenia and 
non-affective psychosis. [42, 46-48] The comorbidity of MS on the one hand and the major 
psychiatric disorders schizophrenia, bipolar disorder and depression, on the other, may 
indicate common underlying mechanisms. For example, shared pathogenic processes and 
environmental or familial risk factors may explain the simultaneous presence of MS and 
psychiatric illness. Previous studies have shown an increased risk for schizophrenia and 
depression in first-degree relatives to MS patients compared with controls. [38, 41, 48]. But, 
some studies have limited statistical power because of small sample sizes and some results 
have been contradictory and difficult to interpret. 
 
1.3 NEUROINFLAMMATION, TRYPTOPHAN METABOLISM AND 
PSYCHIATRIC DISORDERS 
1.3.1 Is inflammation linked to psychopathology? 
The immune system is our primary defense against infections and is also activated in 
response to body injuries and ischemia to initiate reparation procedures. Thus, it may seem 
surprising that dysregulation of the immune system plays an important role in the etiology of 
schizophrenia and bipolar disorder. The immune system, however, is not only activated in 
response to foreign invaders and trauma, but is also activated in many somatic disorders (e.g., 
cardiovascular disease, diabetes type 2 and autoimmune disorders) [49]. Epidemiological data 
show that many somatic disorders mediated by inflammation come into clusters with 
psychiatric disorders. Register studies, for instance, have shown that patients with 
autoimmune disorders (e.g., MS, autoimmune thyrotoxicosis, systemic lupus erythematous, 
Guillain-Barré syndrome, and autoimmune hepatitis) are at increased risk of schizophrenia or 
bipolar disorder [50, 51]. Patients with bipolar disorder and schizophrenia also have an 
elevated risk to develop cardiovascular disease and diabetes type 2 [52]. Similarly, genetic 
studies provide evidence for involvement of the immune system, especially in schizophrenia 
in which many shared susceptibility genes have been found in the immune-related human 
leukocyte antigen region of the human genome [53, 54]. The C-reactive protein (CRP) is an 
inflammatory marker commonly used in medical practice and recent meta-analysis has shown 
that CRP is increased in schizophrenia as well as in bipolar disorder [55, 56]. 
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1.3.2 The immune system 
The peripheral immune system is divided into two parts: the innate and the acquired immune 
system. The innate (non-specific) immune system is mediated by dendritic cells and 
macrophages of monocyte origin that identify pathogens through the toll-like receptors with 
the capability to recognize patterns of foreign elements. When activated, phagocytosis of 
pathogens is induced and a cascade is initiated leading to a release of cytokines to recruit 
inflammatory cells to the site of action. The acquired (adaptive) immune system consists of T 
and B lymphocytes with the ability to remember previous infections through antigens that 
allows a more effective response if the body is invaded by the same intruder a second time 
[57]. 
The immune system of the CNS differs from the peripheral system. Because of the vital 
function of the CNS, it is well protected and the blood-brain-barrier regulates the transport 
into the CNS. Microglia, a specialized subtype of cells of myeloid origin within the CNS, is 
involved in many of the central immune functions, related to both the innate and acquired 
immune system, including phagocytosis, antigen presentation to activate T-cells and 
production of inflammatory compounds such as cytokines [58]. 
 
1.3.3 The tryptophan metabolism – essential for psychiatric well-being 
Tryptophan is an essential amino acid in the diet and is probably best known to form 
serotonin. In the brain serotonin has important functions (such as regulation of mood and 
appetite) and serotonin may be converted into the hormone melatonin, a regulator of the 
circadian rhythm. Nevertheless, most of the tryptophan is degraded through the kynurenine 
pathway, where tryptophan is converted into kynurenine and transported from the periphery 
into the CNS. Kynurenine is then degraded into kynurenic acid or quinolinic acid both of 
which pass through the blood-brain barrier poorly [59]. Quinolinic acid is in turn degraded 
into the end product nicotinamide adenine dinucleotide with an essential role in the 
metabolism of the body [60]. Enzymes of importance for the kynurenine pathway of the 
tryptophan metabolism are indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase, 
and indoleamine 2,3-dioxygenase is known to be induced by cytokines (e.g., interferons) [61-
63]. 
Kynurenic acid is a potent antagonist of the N-metyl-D-aspartate (NMDA) and α-7-
acetylcholin receptors [60]. In recent years special interest has been directed towards the 
metabolite because it is the only endogenous antagonist of the NMDA receptor. The NMDA 
receptor, stimulated by glutamate and glycine, is of particular interest for psychosis because a 
blockade of the receptor by the exogenous NMDA antagonist phencyclidine has been shown 
to affect the extracellular dopamine levels in the brain and induce psychotic symptoms [64, 
65]. 
 
1.3.4 Amyloids and neurocognitive dysfunction 
Cognitive impairment is a major symptom in both schizophrenia and bipolar disorder [8-10] 
but the mechanisms underlying the cognitive decline are unknown. In a disorder such as 
Alzheimer’s disease with severe progressive cognitive decline the main pathological 
mechanism is the accumulation of amyloid-β-containing (Aβ) plaques and intracellular 
neurofibrillary tangles consisting of tau proteins [66, 67]. The normal physiological function 
of tau proteins is to stabilize the neuronal microtubules while the function of Aβ is not 
exactly known. In Alzheimer’s disease accumulation of Aβ is thought to induce innate 
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immune responses through activation of microglia, which may contribute to the progressive 
neurodegeneration [68]. 
Considering the cognitive dysfunction in psychosis, disturbances of the amyloid turnover 
may also be of interest to investigate in psychotic disorders. A few studies have shown 
deviations in the CSF levels of Aβ-related proteins in schizophrenia [69] and bipolar disorder 
[70]. In a study on elderly schizophrenia patients Aβ-42 was found to be lower compared 
with controls but higher compared with Alzheimer patients, whereas tau CSF levels were 
normal [69]. Aβ is generated through cleavage of the amyloid precursor protein. In a study on 
bipolar patients the soluble form of amyloid precursor protein α and β were found to be 
lower. No differences were seen in Aβ in bipolar patients compared to controls, but higher 
ratios of Aβ-42/Aβ-38 and Aβ-42/Aβ-40 were found in the bipolar patients [70]. Thus, there 
seem to be abnormalities in Aβ metabolism also in psychiatric disorders, although the pattern 
seems to differ from Alzheimer’s disease. 
 
1.4 CEREBROSPINAL FLUID BIOMARKERS IN SCHIZOPHRENIA AND 
BIPOLAR DISORDER 
1.4.1 Cerebrospinal fluid  
A useful substrate for biomarker discovery is CSF because of its proximity to the brain [5]. 
CSF is a colorless fluid, surrounding the neurons and glia of the CNS and is secreted 
predominantly by the choroid plexus in the lateral, third and fourth ventricles. The total 
volume remains constant at 100–150 ml and is located in the ventricular system, the 
subarachnoid space, brain parenchyma and the spinal canal. The fluid is turned over four 
times a day, as 500 ml is produced daily; the fluid is drained via arachnoid granulations into 
the bloodstream [71]. CSF may be obtained by lumbar puncture using a needle inserted in the 
vertebral interspace at the L3-L4 or L4-L5 level. 
The blood-CSF barrier limits the passage of molecules into the CSF from the blood to 
maintain an optimal environment for the neurons of the CNS. Albumin exclusively originates 
from the blood [72]. Thus, increased leakage of albumin into the CSF may be used as a 
measure of a worsened function of the blood-CSF-barrier by calculating the CSF/serum 
quotient, an. albumin ratio [72, 73]. An increased albumin ratio is found in CNS infections, 
Guillan Barré syndrome, brain tumors and cerebrovascular disorders [74]. An increased 
albumin ratio is also present in bipolar disorder and chronic as well as anti-psychotic naïve 
schizophrenia patients [75, 76]. The evidence achieved so far indicates that there is a 
disturbed blood-CSF barrier function in schizophrenia and bipolar disorder that is not related 
to antipsychotic medication, although the study on bipolar patients could not exclude such an 
effect [75]. 
 
1.4.2 Neuroinflammatory biomarkers 
Macrophages (in periphery) and microglia (in CNS) express the protein CD14, which is a co-
receptor. They are accompanied by the toll-like receptors, with the ability to detect bacterial 
lipopolysaccharide. CD14 is attached to the membrane as mCD14 and after activation of the 
immune system it is shed from the membrane into the circulation in a soluble form, i.e. as 
sCD14 [77-80]. It has been shown to be increased in chronic inflammatory disorders (e.g., 
cardiovascular disease [81] and rheumatoid arthritis [82]). Thus, sCD14 may be used as a 
marker of inflammation; higher levels of sCD14 indicate inflammation. Another 
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inflammation marker is “Chitinase 3 like protein 1” (YKL-40 or CHI3L1), which is a protein 
secreted by macrophages and microglia, among others, and has a role in inflammation and 
tissue remodeling [83]. Increased serum levels of sCD14 are associated with schizophrenia 
and bipolar disorder [84] and elevated CSF-levels of sCD14 and YKL-40/CHI3L1 were 
previously found in patients with bipolar disorder [85]. 
Cytokines are small proteins with functions in cell signaling processes that include 
chemokines, interferons (IFN), interleukins (Il), lymphokines and the tumor necrosis factor 
(TNF) proteins. Many studies have focused on measuring various kinds of cytokines in the 
blood and CSF of schizophrenia and bipolar patients to learn more about potential immune 
function abnormalities in psychiatric disorders. 
Studies on serum have shown that the cytokines Il-1β, Il-6 and TNF-α have a significant 
influence on psychiatric disorders and psychosis in particular. For instance, a meta-analysis 
of studies on drug-naïve first episode psychotic patients reported associations between 
increased serum levels of the cytokines Il-1β, Il-6 and TNF-α and psychosis [86]. A meta-
analysis on bipolar disorder found significant associations with increased serum levels of 
TNF-α only; and instead another interleukin, Il-4, was significantly increased [87]. Studies on 
CSF are fewer than those on serum. A CSF study on Il-1β showed higher levels in first-
episode schizophrenia patients compared with healthy individuals [88] and chronic 
schizophrenia patients displayed elevated CSF levels of Il-6 compared with controls [89, 90]. 
But, a number of studies did not show any group differences [91]. Higher levels of Il-1β and 
lower levels of Il-6 were also found in euthymic bipolar patients [88], whereas screening for 
eleven cytokines in 121 patients with bipolar disorder only showed increased levels of Il-8 
with no difference found for Il-1β, Il-6, and TNF-α [92]. 
Chemokines also seem to be of interest for psychiatric disorders and the chemokine 
“monocyte chemotactic protein 1”, also called “chemokine ligand 2” (MCP-1 or CCL2) 
activates macrophages, T-lymphocytes and dendritic cells to the site of inflammation. It has 
been shown to be elevated in serum in bipolar disorder as well as in schizophrenia, although 
the study samples have been limited [93]. In bipolar patients and their offspring the 
expression of MCP-1 mRNA in monocytes was also upregulated [94]. 
Alterations in the tryptophan metabolism and more specifically in the kynurenic pathway 
have been found in numerous CNS disorders such as bacterial meningitis [95], Alzheimer’s 
disease [96] and MS [97] as well as in traumatic brain injury [98]. Elevated CSF levels of 
kynurenine and kynurenic acid have been found in patients with schizophrenia [99, 100] and 
elevated CSF levels of kynurenic acid have been found also in bipolar disorder [101]. A 
recent study suggests that an increased production of kynurenic acid in relation to quinolinic 
acid might be of significance for schizophrenia [62]. The tryptophan metabolism appears to 
be interconnected with the immune system for instance through the enzyme indoleamine 2,3-
dioxygenase that is activated by the cytokines INF-γ and TNF-α [63]. 
 
1.4.3 Microscopic structures 
Electron microscopy techniques to examine CSF have been successfully performed to 
identify infectious germs such as the human immunodeficiency virus [102]. In 2002, 
micrometer-sized structures were identified in fresh CSF from schizophrenia patients using 
the scanning electron microscopy technique [103] and some years later structures were also 
identified in patients with bipolar disorder [104]. However, in a separate investigation , in 
Finland using frozen CSF samples from schizophrenia patients and different methodologies 
no association was observed between structures in CSF and schizophrenia [105]. 
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The identified structures have typically spherical shapes and the sizes average from 0.5-1 µm, 
(Figure 2). The structures are smaller than cells but larger than protein molecules and the 
shape may indicate high lipid contents. Yet, it has been difficult to learn more about the 
biochemical properties of the particles and staining with antibodies did not give any 
conclusive results (unpublished data). Possible hypotheses of the origin of the structures are 
that they are waste products (e.g., from inflammatory processes or degeneration of brain 
tissue) or that they result from a reduced cleaning function of the CSF. 
 
 
Figure 2 Example of structures in the CSF of a patient with schizophrenia. The same area 
on the filter is displayed in four magnifications: In picture A. 80 times, B. 350 times, C. 
1500 times and D. 5000 times magnification. Structures with a donut shape and a diameter of 
0.5-1 µm that seem to originate from the larger complex (in the lower left-hand corner) can 
be viewed in this picture. The dark circles in the upper part of the picture represent the pores 
in the filter with a size of about 0.5 µm in diameter. (Photos: Sten Johansson and Viktoria 
Johansson, unpublished data). 
 
1.4.4 Microparticles (microvesicles) 
The phenomena of microparticles, also designated as microvesicles, were first described by 
Wolf in 1967 [106]. Microparticles are formed when cells, induced by activation, stress or 
apoptosis, release a part of the membrane forming small rounded particles. The small 
particles are thought to be involved in signaling processes and transportation procedures 
between cells. The size may range from 0.3-1 µm and the particles are composed by proteins, 
lipids and genetic material from its parent cell. It is thereby possible to analyze its original 
cell-type. [107]. The possibility to analyze its origin make microparticles suitable as a 
 - 9 - 
 
biomarker for cell activation, but further research is needed to explore its potential role in 
psychiatric disorders. 
 
1.5 GENETICALLY SENSITIVE STUDY DESIGNS 
Epidemiology is a science in which health and disease conditions are studied in populations 
to learn about causes, risk factors and health outcomes. A study design is chosen to be able to 
answer a specific research question in the best way. Examples of study designs often used are 
cohort studies, case-control studies and case series [108]. Epidemiological studies are usually 
designed to measure the relationship between an exposure and an outcome. Another type of 
study design is the genetically sensitive designs used in twin and family studies that measure 
the environmental and genetic influence on the phenotype. 
 
1.5.1 Twin studies 
Of all births, 1-2 % are twin births and about 30% of the twin pairs born are monozygotic 
(MZ), which means that they have developed from the same ovum [109]. MZ twins, also 
known as identical twins, share 100% of their genes. Dizygotic twins (DZ), also called 
fraternal twins, share on average 50% of their genes and are not more alike than siblings 
[110]. In the DZ twin pairs about half have the same sex. For research purposes, it is most 
common to use same sexed twins. 
Identical twins are assumed to share the genetic setup by 100% and fraternal twins by 50%. 
Both MZ and DZ twins share the intrauterine environment, and later on (if reared together) 
they share to a higher degree upbringing, childhood experiences and other environmental 
factors such as exposures to early infections. Therefore, MZ and DZ twins are assumed to 
completely share early environmental factors  
In the classical twin model the incidence of a disorder in both twins of a pair (the 
concordance rate) is compared between MZ and DZ twins. Such a comparison makes it 
possible to estimate the heritability of the disorder of interest. Nowadays heritability 
estimation of a certain disorder or trait is performed by using structural equation modelling in 
the “ACE-model” where three components are estimated: additive genetics “A”, shared early 
environmental factors “C”, and unique environmental factors “E”. 
Co-twin control analysis is performed on twin pairs that are discordant to a disease or 
exposure. It means that one twin in a pair has a disease, whereas the other does not. By 
comparing the twins within a pair it is possible to investigate a risk factor while controlling 
for genetic and shared environmental confounding within the twin pair. The diseased twin in 
the pair is referred to as the “proband” and the healthy twin as the “co-twin”. First, the 
probands may be compared with external control twins to determine whether there is an 
association between exposure and outcome. Second, a co-twin control analysis is performed 
in which the probands and co-twins are compared within the MZ and DZ pairs, which 
controls for confounding from shared environmental factors. In a third step the proband and 
co-twins are compared within the MZ pairs to control for genetic confounding [110, 111]. 
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1.5.2 Sibling designs 
Similar principles may be used in sibling design methods. Sibling methods are ideal to study 
unusual exposures and outcomes because, in comparison with twin studies, it is possible to 
investigate larger population samples. Siblings share on average 50% of their genes, but do 
not share early environmental factors as twins do because they were not born or reared at the 
same time. Suppose that there is an association between disease A and B and you want to 
ascertain whether the association is affected by genetic factors. Siblings to individuals with 
disease A may be considered as exposed to a genetic liability for disease A, whereas siblings 
to non-affected individuals are unexposed. Then the risk for disease B is compared in siblings 
exposed to A and the siblings that are not exposed. If there were differences in risks between 
the exposed and non-exposed siblings, genetic factors are of importance for the relationship 
between disease A and B.  
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2 AIMS 
The overall aim of this thesis was to study the hereditary and environmental properties of 
potential biomarkers for schizophrenia and bipolar disorder in CSF by using twin pairs. In 
addition, the intention was to explore the comorbidity between schizophrenia, bipolar 
disorder, depression and MS. The aim of each individual study is as follows: 
Study I: To study the hereditary and environmental properties of previously identified 
microscopic structures in the CSF of twins with schizophrenia and bipolar disorder. 
Study II: To study the presence of microparticles/microvesicles in CSF from a twin pair 
with schizophrenia and healthy controls and to study over time the stability of the 
microscopic CSF structures from Study I. 
Study III: To study the hereditary and environmental properties of microglia- and amyloid 
biomarkers in the CSF of twins with schizophrenia and bipolar disorder and their relation to 
previously identified microscopic structures. 
Study IV: To study the hereditary and environmental properties of tryptophan metabolites 
and cytokines in twins with schizophrenia and bipolar disorder and their relation to 
psychometric scales. 
Study V: To study comorbidity and sibling risk in schizophrenia, bipolar disorder and 
depression in relation to MS. 
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3 MATERIALS AND METHODS 
3.1 SUMMARY OF STUDIES 
Table 1. This thesis is based on the following studies. Note that the study samples are partly 
overlapping in Study I-IV. STAR: The Schizophrenia Twins and Relatives. CSF: Cerebrospinal fluid. SBP: 
St. Göran Bipolar Project. MS: Multiple sclerosis 
 Type of study Population Materials & Methods Statistical analysis 
I Twin study 37 twins from the STAR 
study 
65 singletons from SBP 
Structures in CSF were 
identified with scanning 
electron microscopy. 
Exposure : Microscopic 
structures 
Outcome: Presence of 
bipolar disorder 
/schizophrenia or liability to 
psychiatric disorder. 
The association between a 
psychiatric disorder/ 
liability and CSF-structures 
were computed using 
conditional logistic 
regression. 
II Case series One twin pair from the 
STAR study 
4  + 10 singletons from 
SBP 
Microparticles/ 
microvesicles were analyzed 
in CSF 
Descriptive data of the 
findings in twins with 
schizophrenia and healthy 
controls. 
III Twin study 35 twins from the STAR 
study 
(17 complete pairs) 
 
Immune/amyloid biomarkers 
were analyzed in CSF. 
Exposure: Bipolar 
disorder/schizophrenia 
Outcome: CSF-biomarker 
deviations 
Paired t-test, Wilcoxon 
signed rank test and linear 
mixed models were used 
for group differences. 
Spearman's/ Pearson's 
coefficients for 
correlations. 
IV Twin study 23 twins from the STAR 
study 
(10 complete pairs) 
Tryptophan metabolites and 
cytokines were analyzed in 
CSF. 
Exposure: Bipolar 
disorder/schizophrenia 
Outcome: CSF-biomarker 
deviations 
Wilcoxon signed rank, Chi-
square or Fisher exact tests, 
as well as linear mixed 
models were used for 
group differences. 
Spearman's coefficients for 
correlations. 
V Matched cohort 
study 
71 134 schizophrenia/ 
bipolar disorder patients* 
172 479 depression 
patients* 
118 374 siblings to 
schizophrenia/ bipolar 
disorder patients* 
280 577 sibling to 
depression patients* 
16 608 MS-patients* 
26 506 sibling to MS-
patients* 
Exposure: Psychiatric 
disorder/MS or Sibling with 
psychiatric disorder/ Sibling 
with MS 
Outcome: MS or Psychiatric 
disorder 
The risk of MS/psychiatric 
disorder was estimated 
using Cox proportional 
hazards with robust 
sandwich estimates. 
*10 controls were randomly selected per patient/sibling pair matched by birth year and sex 
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3.2 STAR – A SWEDISH TWIN COHORT 
The Schizophrenia Twins and Relatives (STAR) study is a Swedish twin-cohort consisting of 
383 same-sex twins (159 complete twin pairs) born between 1942 and 1986 with twin pairs 
concordant or discordant for schizophrenia, schizoaffective disorder or bipolar disorder and 
non-affected control pairs. All twins have undergone careful psychiatric assessment, 
neuropsychological testing, genotyping, magnetic resonance imaging (MRI) and fMRI 
scanning, all described in detail below. The cohort is one the largest of its kind with the 
intention to learn about the genetic and environmental mechanisms underlying schizophrenia 
and bipolar disorder. 
 
3.2.1 Selection of twins 
In total, 1213 twins, including 602 complete twin pairs, where both were alive, were 
identified from the Swedish Twin Register and the National Patient Register. If one member 
in a pair had a treatment episode of schizophrenia, schizoaffective disorder or bipolar disorder 
the pair was invited to participate. In addition, non-affected control twin-pairs (five pairs for 
each affected pair) were randomly selected and matched by birth year and sex (Figure 3). 
 
 
Figure 3. Flowchart of the recruitment of twins in STAR and the pairs recruited for the 
CSF-study. SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorders, SCID-II: Axis II Disorders, 
GAF: Global Assessment Function scale, SANS: Scale for Assessment of Negative Symptoms, SAPS: Scale for 
Assessment of Positive Symptoms, HDRS: Hamilton Depression Rating Scale, YMRS: Young Mania Rating 
Scale, SPQ-B: Schizotypal Personality Questionnaire-Brief, BIS-11: Barratt Impulsiveness scale, ZSSS: 
Zuckerman sensation seeking scale, Temps-A: Temperament scale, fMRI: Functional Magnetic Resonance 
Imaging, MADRS-S: Montgomery Åsberg Depression Rating Scale-Self assessment, CSF: Cerebrospinal fluid. 
 
3.2.2 Assessment of twins 
In total, 159 complete twin pairs and 37 singe twins (where only one in the pair agreed to 
participate) took part in the psychiatric evaluation. Before the clinical assessment the study 
participants completed screening forms of the Structured Clinical Interview for DSM-IV Axis 
I Disorders (SCID-I) and Axis II Disorders (SCID-II) and the following questionnaires: the 
Schizotypal Personality Questionnaire-Brief (SPQ-B) [112], the Barratt Impulsiveness scale 
[113], the Zuckerman sensation seeking scale [114] and the Temperament scale [115]. A 
psychiatrist or a doctor under psychiatric training administered the interviews of SCID-I 
[116], SCDI-II [117] and rated the participants with the Scale for Assessment of Negative 
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Symptoms (SANS) [118], the Scale for Assessment of Positive Symptoms (SAPS) [119], the 
Hamilton Depression Rating Scale [120], the Young Mania Rating Scale (YMRS)[121] and 
the Global Assessment Function scale (GAF) [122]. Information on socioeconomic status, 
smoking habits, and somatic status was collected. The twins were also tested with a 
neuropsychological battery and were scanned with MRI as well as fMRI. A blood sample 
was taken for zygosity determination and DNA and RNA analysis. Exclusion criteria 
included history of head injury with loss of consciousness, mental retardation, and substance 
use disorder within the past six months, inability to read or comprehend Swedish and any 
condition that precluded MRI scan of the brain (e.g., metal implants, shrapnel and certain 
heart operations). In addition control twins were excluded if they had a personal or family 
history of schizophrenia, schizoaffective disorder, or bipolar disorder. 
 
3.2.3 Zygosity testing 
In the Swedish twin register, zygosity (i.e. if a twin pair was MZ or DZ) is partly based on the 
following two survey questions: 
 
1) “During childhood, were you and your twin partner as alike as ‘two peas in a pod’ or not 
more alike than siblings in general?” 
2) “How often did strangers have difficulty in distinguishing between you and your twin 
partner when you were children?” 
 
If both twins in a pair responded “like two peas in a pod” to the first question or “always or 
almost always” to the second question, the twins were determined as MZ. A validation study 
on DNA proved a correct result in 99% of the cases [110].  
 
The most reliable method to determine zygosity is to compare genetic variation in the 
genome by DNA testing. A set of genetic markers is preferably chosen to show a large 
variation within the population and a low correlation between each other; the markers should 
not be associated with certain diseases [123]. In this thesis, based on a subset of STAR cases, 
twin zygosities are based on a method developed and validated by Hannelius and co-workers. 
The method consists of a highly multiplexed panel of 47 single nucleotide polymorphisms 
including one sex-specific marker [124]. The validation of the method showed that the 
frequency of false positives was < 0.01 when a genotype error of 1% was assumed. The 
analysis showed that 21 twins were MZ and 16 twins were DZ. Of the MZ twins one pair 
did not fulfill the criteria of being MZ according to the survey questions. All 16 twins 
determined as DZ in the DNA analysis fulfilled the DZ criteria according to the survey. 
 
3.3 CEREBROSPINAL FLUID IN TWINS 
3.3.1 Selection of twins for lumbar puncture 
After participation in the STAR-study MZ and DZ pairs that were discordant for 
schizophrenia, schizoaffective disorder or bipolar disorder according to the SCID-I-interview 
were asked if they wanted to participate in the CSF-study. Some pairs were also recruited as 
non-affected control pairs and concordant pairs. Totally, 37 twins in 18 complete pairs agreed 
to participate in this substudy (Figure 4). One of the twins in a pair did not agree to 
participate in the lumbar puncture and was therefore not included in the study. For a complete 
listing of the twins, see table in Appendix (Appendix Table). 
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Figure 4 Overview of the twins that participated in the CSF study and number of 
concordant, discordant and non-affected twin pairs. MZ: Monozygotic, DZ: Dizygotic 
 
3.3.2 Sampling of blood and cerebrospinal fluid 
In Study I-IV paired samples of blood and CSF were collected between 8 and 11 am, in a 
fasting state. The samples were collected from March 2008 until September 2011 and were 
performed on the same day except for one pair who was examined within 43 days. Lumbar 
puncture was performed by an experienced neurologist with the patient in a sitting position. 
One of two types of fine disposable needle was used: Becton Dickinson 22 GA 3.00 IN, 
0.70675 mm (“Quincke needle” used in 26 twins) or Whitaker Needle 25 GA 3.50 IN, 
0.50690 mm (“Sprotte needle” used in 12 twins). The skin in the lumbar region was washed 
with sterile cotton swabs and chlorhexidine 5 mg/mL (Fresenius Kabi) before puncture. The 
needles were inserted in the vertebral interspace L3/L4, or L4/L5. The first drops of CSF, 
approximately 0.6 mL, were collected to be used for microscopic examination and 
(designated fraction I). The following 12 mL of CSF were then collected, gently inverted to 
avoid gradient effects. Another 0.6 ml were collected for microscopic examination 
(designated fraction II) and the remaining CSF was divided into 1.0–1.6 ml aliquots that were 
stored at 80 degrees Celsius awaiting analysis. 
In Study II paired blood and CSF samples were collected a second time (October 2011) from 
one MZ twin pair that had agreed to participate in the study three years after the first visit. 
Lumbar punctures were performed as described above using a “Sprotte needle”. The first two 
drops (100 μL) was collected for microscopic examination and the following 50 μL 
(designated fraction I) were collected in a sterile test tube for immediate flow cytometry 
analysis of microparticles described under 3.3.4. Two additional samples were collected for 
flow cytometry analysis the second one after approximately 7 ml of CSF had been drained 
(designated fraction II) and the third sample after approximately 14 ml of CSF (designated 
fraction III). 
 
 - 16 - 
 
3.3.3 Preparation of cerebrospinal fluid and gold coating  
To prepare for investigation with microscopy (Study I-III) the two separate CSF fractions 
(200 µL) were pipetted and dripped onto the surface of a polycarbonate filter (Nucleopore, 
Inc., Pleasanton, CA, USA) with 0.6 µm pores. The filters were specially prepared by GP 
Plastic AB (Gislaved, Sweden) and supplied by Sempore AB (Stockholm, Sweden). The 
filter was then fitted to an airtight device designed with flow channels that allow CSF to 
stream in the direction of the center of the filter when vacuum suction is applied from below. 
The design does not allow particles with sizes larger than 0.6 µm to pass through and the 
remaining structures in the CSF are allowed to concentrate in the center of the filter. After 
dehydration the filter was gold coated in a JEOL JFC-1200 Fine Coater (JEOL Tokyo, Japan) 
during two min with ionized gold to a thickness of 40 Å. 
 
3.3.4 Scanning electron microscopy 
The filters (Study I-III) were analyzed in a scanning electron microscope (Philips High 
Resolution SEM 515, Philips Electronic Instruments, Eindhoven, The Netherlands). The total 
area of each filter with a diameter of one cm was examined in the microscope and rated by an 
experienced researcher. The peripheral area outside the center was mostly free of structures. 
To standardize the procedure, microscopic images of the central areas of the filters were 
enlarged 50, 500 and 2000 times and saved for further reference. 
A second researcher rated independently the same images with similar results. [6]. The 
microscopic quantity of the morphological structures on each filter was rated in the following 
four categories: 0= none, 1 =few, 2= several and 3= many structures as described previously 
[104]. Particles larger than 0.6 mm and some with smaller diameters (down to 0.1 mm) were 
revealed. 
 
3.3.5 Flow cytometric analyses of microparticles in blood and cerebrospinal 
fluid 
All blood and CSF samples in the analysis of microparticles were analyzed freshly within one 
hour after the collection procedure (Study II). Blood samples were centrifuged at 2000 xg for 
20 min at room temperature to obtain platelet poor plasma. Before flow cytometric analysis 
samples were again centrifuged at 2000 xg for 20 min and the supernatant was then 
centrifuged again at 13,000 xg for 2 min. Twenty microliters of the sample were then 
incubated with the following antibodies: phalloidin-Alexa-660 (Invitrogen, Paisley, UK), 
lactadherin-FITC (Haematologic Technologies, VT, USA), CD42a-PE (BD,NJ, USA), 
CD144-APC (AH diagnostics, Stockholm, SWE) and CD45-PC7 (Beckman Coulter, CA, 
USA). The results in plasma are reported as absolute numbers of microparticles (106 MPs/L) 
(microparticles counted×standard beads added/L)/standard beads counted (FlowCount, 
Beckman Coulter, CA, USA). 
Twenty microliters of the CSF samples were incubated for 20 min in dark with the same 
antibodies as described above. The microparticle-gate was determined using Megamix 
beads (BioCytex, Marseille, France), which is a mix of three beads with diameters of 0.5 
μm, 0.9 μm and 3 μm. Microparticles were defined as particles less than 1.0 μm in size, 
negative to phalloidin (in order to exclude cell membrane fragments) and positive to 
lactadherin (which binds to phosphatidylserine). Later the microparticles were sorted into 
particles positive for CD42a (platelet origin; GPIX), CD144 (endothelial origin, VE-
cadherin) or CD45 (leukocyte origin; pan-leukocyte antigen). Conjugate isotype-matched 
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immunoglobulin (IgG1-FITC, IgG1-PE, IgG1-APC and IgG1-PC7) with no reactivity 
against human antigens was used as a negative control to define background noise in the 
cytometry analysis. The results are presented as number of microparticle events in the 
microparticle-gate during 45 seconds of measurement. 
 
3.3.6 Analysis of amyloid- and microglia related biomarkers 
 
In Study III, amyloid and microglia markers were performed. CSF levels of Aβ38, Aβ40, 
Aβ42, sAPP-α and sAPP-β and MCP-1 were measured using the MSD ® Human/Rodent 
(4G8) Abeta-Triplex Assay, MSD® sAPP-α/sAPP-β Multiplex Assay, and MSD® Human 
MCP-1 Ultra-Sensitive Kit respectively, as described by the manufacturer (Meso Scale 
Discovery, Gaithersburg, MD, USA). CSF levels of total-tau (T-tau), hyperphosphorylated-
Tau (P-tau), and Aβ1-42 were measured simultaneously by Luminex xMAP technology using 
the Inno-Bia AlzBio3 kit (Innogenetics, Zwijndrecht, Belgium). sCD14 and YKL-40 were 
measured by Human sCD14 quantikine ELISA kit and Human chitinase-3 quantikine ELISA 
kit, respectively (R&D systems, Inc, Minneapolis, MN, USA). 
 
3.3.7 Analysis of tryptophan metabolites 
In Study IV, to quantify the CSF concentrations of tryptophan, kynurenic acid and quinolinic 
acid, high-performance liquid chromatography and gas chromatography-mass spectrometry 
methods were used. The methods have been previously described in detail by Linderholm 
et.al. (2012) and in the Thesis of Magdalena Kegel (Dysregulation of the kynurenine pathway 
in psychotic disorders: immunological aspects Chapter 3.4, page 47-51) [100, 125]. 
 
3.3.8 Analysis of cytokines 
Cytokines were analyzed in Study IV. The CSF samples had been thawed once before this 
analysis was carried out. IL-1, IL-6, IL-8 and TNF-were quantified in CSF using a 
customized Human Ultra-Sensitive 4-Plex Kit (MesoScale Discovery®, Gaithersburg, MD, 
USA) in 2012. The assays were analyzed as per the manufacturers protocol 
(http://www.mesoscale.com), with modification of a longer primary incubation time 
(overnight at 4°C) and a sample volume of 50 l. Intra-assay coefficient of variation was 
below 20% for all samples presented. The limit of detection  in our analysis was: IL-1 (0.19 
pg/ml), IL-6 (0.05 pg/ml), IL-8 (0.04 pg/ml) and TNF- (0.08 pg/ml). The methods have 
previously been described in detail [125]. 
 
3.4 SINGLETON CONTROL SUBJECTS 
In Study I, individuals serving as controls (n=65) were included from the St. Göran Bipolar 
Project (SBP), a prospective study on patients with bipolar disorder. In Study II, controls 
were included from the SBP (n=10). 
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3.4.1 Selection of singleton controls 
Healthy volunteers residing in the Stockholm area were randomly selected for the study from 
the Total Population Register by Statistics Sweden. The participants were matched on sex and 
age with bipolar patients previously enrolled in the SBP. Exclusion criteria were any ongoing 
psychiatric disorder, current treatment with any psychotropic drugs, having a first-degree 
relative with schizophrenia, schizoaffective disorder or bipolar disorder and any condition 
that precluded MRI scan of the brain. 
 
3.4.2 Assessment of controls 
As first step research nurses with psychiatric training telephone interviewed eligible 
participants. The participants who fulfilled the screening criteria were scheduled for 
participation in the study. In a second step the participants were interviewed by a psychiatrist 
using a Swedish modified version of the Affective Disorder Evaluation assessment tool 
[126]. This interview includes, except for the screening for bipolar illness, questions about 
socioeconomic status, use of alcohol and psychoactive substances, family history of 
psychiatric disorders in first- and second-degree relatives, treatment history and somatic 
illnesses. To screen for psychiatric disorders other than bipolar illness The Mini International 
Neuropsychiatry interview (MINI) was used [127]. Further the controls were rated using the 
GAF scale [122]. Finally, the participants completed self-report questionnaires: the YMRS 
[121], MADRS [128], the Alcohol Use Disorders Identification Test (AUDIT) [129] and the 
Drug Use Disorders Identification Test (DUDIT) [130] (Figure 5). 
 
 
Figure 5. Flowchart of the recruitment of singleton controls in the St. Göran Bipolar 
Project. ADE: Affective Disorder Evaluation, MINI: The Mini International Neuropsychiatry interview, GAF: 
Global Assessment Function scale, YMRS: Young Mania Rating Scale, MADRS-S: Montgomery Åsberg 
Depression Rating Scale-Self assessment, AUDIT: Alcohol Use Disorders Identification Test, DUDIT: Drug Use 
Disorders Identification Test. 
 
3.4.3 Sampling of cerebrospinal fluid and blood in controls 
Sampling of CSF and blood in the controls was performed from November 2009 to 
December 2010; the sampling procedure followed the same scheme as described under 3.3.1. 
In Study II, in four of the controls the sampling of blood and CSF took place in October 2011 
in order to analyze the blood and CSF with flow cytometry within an hour after sampling.  
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3.5 REGISTER DATA 
Data from the national registers of Sweden have been used to identify participants in all 
studies of the thesis. The participants in the studies were identified from the personal 
identification number which is a ten digit code assigned to each Swedish resident. 
 
3.5.1 The Swedish Twin Register 
The Swedish Twin Register was established in the 1950s and is one of the world’s largest 
twin databases, including more than 194,000 twins born from 1886 and onwards [131]. 
Among other information, the register includes information about twin status and sex. 
 
3.5.2 The Swedish National Patient Register 
The Swedish National Patient Register (National Board of Health and Welfare, 
http://www.socialstyrelsen.se) is a nationwide register that includes information on 
psychiatric inpatient care from 1973 and specialist care from 2001. Information on somatic 
diagnoses (e.g. MS) is covered from 1987. The diagnoses are recorded according to the ICD 
8, 9 and 10 [2, 132, 133] and the register has a high level of agreement with medical and 
psychiatric diagnoses according to a validation study [134]. 
 
3.5.3 The Swedish MS Register 
The Swedish MS Register [135] was started in 1996 and contained information on 13,558 
unique individuals (up to January 1, 2010). All MS diagnoses are decided by consultant 
neurologists [136]. 
 
3.5.4 The Multi-Generation Register 
The Multi-Generation Register (Statistics Sweden, http://www.scb.se) is a national database 
with information of the biological parents in individuals born in Sweden since 1932 and 
living in Sweden after 1960, as well as of immigrants who became Swedish citizens before 
the age of 18 [137]. 
 
3.5.5 The Cause of Death Register 
The Cause of Death Register provides data on all deaths among Swedish citizens including 
death dates [138]. 
 
3.5.6 The Total Population Register 
The Total Population Register contains information on place of birth, citizenship status, place 
of residence and immigration and emigration from the country. The register is administered 
by the Swedish Tax Agency [139]. 
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3.6 STATISTICAL SOFTWARE 
Statistical Analysis Software (SAS 9.3 or 9.4) or Statistical Package for the Social Sciences 
(IBM SPSS Statistics 21.0) were used for the analyses. 
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4 STUDY DESIGN AND STATISTICAL METHODS 
4.1 STUDY I 
4.1.1 Study design 
CSF from 37 twins and 65 non-affected singleton controls was collected and examined with 
scanning electron microscopy. To be able to analyze the genetic and environmental properties 
of the microscopic structures in the CSF we constructed three groups: probands (twins with 
bipolar disorder, schizophrenia or schizoaffective disorder), co-twins (non-affected twins 
with liability of bipolar disorder, schizophrenia or schizoaffective disorder) and non-affected 
controls. We then predicted the risk of being a proband or a co-twin compared to the control 
group (reference) if the microscopic finding was positive. 
We analyzed the influence of potential confounders such as albumin ratio, body mass index 
(BMI), lifetime alcohol abuse or dependence, lifetime anxiety syndrome, any medical 
disorder, smoking status and inflammatory markers in serum (high sensitivity CRP and white 
blood cell count). The overall effect of psychotropic medication and the different types 
(neuroleptics, lithium, anticonvulsants and antidepressants) were also analyzed. To determine 
the genetic and environmental properties of the CSF-structures differences between MZ and 
DZ twins were tested in the co-twin group. 
 
4.1.2 Statistical method 
An exact conditional logistic regression model was applied to analyze the presence of a 
microscopic finding as the independent (exposure) variable and the risk of being a proband or 
a co-twin compared with the control group as the dependent (outcome) variable. The results 
were expressed as odds ratios (OR) with Wald’s confidence intervals (CI). A two-sided p-
value of 0.05 was considered statistically significant. All analyses were adjusted for age and 
sex and non-independency of the twin pairs was controlled by removing either twin 1 or twin 
2 in the analysis from the concordant pairs. Potential confounders were tested by adding them 
in sequence to the model as covariates. The effect of psychotropic medication was tested 
using logistic regression models with medication (along with age and sex) as the independent 
variable and the microscopic finding as the dependent variable. Fisher’s exact test was 
applied to examine any association between a positive CSF finding and zygosity in the co-
twins (n=12). 
 
4.2 STUDY II 
4.2.1 Study design 
In this case series blood and CSF from one MZ twin pair concordant for schizophrenia and 
four non-affected controls were analyzed for microparticles, of leukocyte, endothelial and 
platelet origin, using flow cytometric analysis. The samples were analyzed within one hour 
after lumber puncture. CSF was analyzed with scanning electron microscopy already three 
years earlier in the twin pair and thus a second microscopic examination could be performed 
to investigate the stability of the structures over time. The scanning electron microscopy 
results were compared with the results from ten singleton controls previously included in 
Study I. The twins were in their 50s at the time of sampling and therefore controls were 
chosen to be as close in age as possible with age ranging from 46 to 64 years. 
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4.2.2 Statistical method 
Only descriptive data are presented. 
 
4.3 STUDY III 
4.3.1 Study design 
Biomarker concentrations of immune related markers (sCD14, YKL-40 and MCP-1) and 
amyloid markers (Aβ-38, Aβ-40, Aβ-42, Aβ-1-42, sAPP-α, sAPP-β and T-tau and P-tau) 
were measured in the CSF of 35 twins (17 complete pairs). The sample included 15 probands 
with either schizophrenia, schizoaffective disorder, bipolar I disorder or bipolar II disorder; 
12 co-twins (of which 11 belonged to complete pairs) and 8 controls (from 4 complete non-
affected pairs). In the main analysis the probands were collapsed into one group of psychotic 
disorders. 
Correlations were computed in all complete twin pairs regardless of diagnostic status (n=17). 
Then a co-twin control analysis was performed in the disease discordant pairs (n=11) and in 
the MZ and DZ pairs separately. Associations between the biomarkers and potential 
confounders were analyzed: albumin ratio, medication (antipsychotics, lithium, 
antidepressants, and anticonvulsants), smoking, BMI and measures of peripheral 
inflammation (high sensitivity-CRP and white blood cell count). Associations between 
biomarkers and psychiatric assessment scales for psychosis was analyzed (SANS, SAPS, 
SPQ-B and the screening version of SCID-II – Cluster A part). 
A positive association has previously been described between sCD14 and albumin ratio [85]. 
To test whether this association was causal we used a MZ twin intra-pair differences model, 
as described elsewhere [140]. The correlation of the intra-pair differences between sCD14 
and albumin ratio was calculated in the MZ and DZ pairs regardless of diagnostic status. In 
addition to the classical co-twin control approach we performed an analysis comparing the 
biomarker concentrations between the probands, co-twins, and controls. However, the model 
was hazardous because of a limited number of controls (n=8). Finally, we also tested for 
associations between microscopic structures and microglia and amyloid biomarkers. 
 
4.3.2 Statistical method 
Correlations were computed using Pearson’s coefficient if data were normally distributed 
(Spearman’s correlation coefficient was applied for non-normal distributions) and Fishers Z-
transformation was used to compute CIs. In the co-twin control analysis of the discordant 
pairs the paired t-test and Wilcoxon signed rank test were used. In the proband-, co-twin-, 
control approach, a linear mixed model with random intercepts shared within each twin pair 
was applied to compensate for the clustered nature of the twin data. The same model was 
applied to analyze the effect of potential confounders, psychiatric assessment scales and 
scanning electron microscopy results on the biomarker levels. In all linear mixed model 
analyses the biomarkers always entered the model as the dependent (outcome) variable. Age 
and sex were added as covariates. Log transformations were applied when the data were not 
normally distributed. Bonferroni correction was used to adjust for multiple testing. 
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4.4 STUDY IV 
4.4.1 Study design 
Kynurenic acid, quinolinic acid, tryptophan, and cytokines (IL-1, IL-6, IL-8 and TNF-) 
were analyzed in CSF from 23 twins (ten complete twin pairs). Within twin pairs, differences 
of the MZ and DZ pairs were calculated and potential differences between the MZ and DZ 
twins were computed by using the Wilcoxon signed-ranks test (Mann-Whitney U-tests). To 
obtain a normal distribution of the data all markers, except for IL-1β, were log transformed. 
Associations between the biomarkers and the results from psychiatric assessment scales were 
measured by using a linear mixed model analysis with random intercepts to account for the 
clustered nature of the data. The following assessment scales were studied: SPQ-B, the 
screening questions of SCID-II (cluster A part including questions for paranoid, schizoid and 
schizotypal personality traits), SANS and SAPS. 
 
4.4.2 Statistical methods 
Characteristics between proband and co-twins, and between DZ and MZ twins were 
compared using Wilcoxon signed-ranks test, Chi-square tests or Fisher exact tests. Log 
transformations were applied on all biomarkers, except for IL-1-α, to obtain a normal 
distribution of the data. Correlations were calculated using Spearman’s correlation 
coefficient. To account for the clustered nature of the data, we fitted a linear mixed model 
with random intercepts shared between twins in a pair. Potential confounders, which were 
identified in the initial analyses (with a p-value of <0.1), were included as co-variates in the 
main model. Co-factors were subsequently removed based on significance of co-factors and 
Akaike’s Information Criterion aiming for a final bestfitted model with fewer parameters. 
Age and sex were included as co-variates in all analyses and two-tailed probability values are 
reported. 
 
4.5 STUDY V 
4.5.1 Study design 
Patients with schizophrenia, schizoaffective disorder, bipolar disorder, depression and MS 
were identified from the National Patient Register. To secure diagnostic specificity we 
required two or more diagnoses from the register. No diagnostic overlap was allowed 
between bipolar disorder, schizophrenia and schizoaffective disorder and patients with 
diagnostic overlap were classified in a separate mixed category designated “Mixed 
bipolar/psychosis". Subgroups were constructed for bipolar patients who had experienced one 
or more episodes of mania, designated “Bipolar disorder type I”, and patients with depression 
who had experienced at least one episode of severe depression, designated “Severe 
depression”. The Swedish MS Register was used to verify the quality of the MS diagnoses 
from the National Patient Register and 96% of the patients with two diagnoses of MS in the 
National Patient Register were registered as having MS in the Swedish MS register. 
 
We used a matched cohort design based on individuals and pairs of siblings living in 
Sweden, identified from register linkages of the Multi-Generation Register, the Cause of 
Death Register and the Total Population Register. Follow-up started in 1987 (or age 18) 
when MS was the event and in 1973 (or age 18) when a psychiatric disorder was the event. 
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Participants were followed until an event occurred or until the participant was censored 
because of death, emigration or end of follow-up, on December 31, 2009 (Figure 6). 
 
 
 
 
Figure 6. Timeline of Study V. The patients were followed from 1987 when multiple 
sclerosis was the outcome, and from 1973 when any psychiatric disorder was the outcome. 
Sensitivity analysis was performed using data from the out-patient register starting in 2001. 
The patients were followed until the end of 2009. 
 
First associations between a psychiatric disorder and the risk of MS were studied in a 
“comorbidity cohort”. Ten unexposed individuals were randomly selected per patient, 
matched by birth year and sex. Second associations between having a sibling with a 
psychiatric disorder and the risk of MS were studied in a “sibling cohort”. All pairwise 
combinations of sibling pairs were considered; for each exposed pair ten unexposed sibling 
pairs were randomly selected, matched for birth year and sex for both individuals in the 
pair. The analysis of the comorbidity cohort and the sibling cohort was also performed in 
reverse order in order to assess the association between MS or having a sibling with MS 
(exposure) and the risk of a psychiatric disorder (outcome). 
 
To address the influence of ascertainment bias in the comorbidity analysis we performed 
two analyses by time period. In the first analysis we explored the risk of MS in three time 
windows. MS risk was analyzed (1) from entry date until two years before date of onset of 
the psychiatric disorder, (2) from two years before until two years after date of onset of the 
psychiatric disorder and (3) from two years after date of onset of the psychiatric disorder 
until end of follow-up. In the second analysis MS risk was measured after date of onset of 
the psychiatric disorder until an event occurred or the participant was censored. Patients 
with an MS event before entry date were censored. All of the above analyses were 
performed in a reverse manner, whereby the risk of a psychiatric disorder was analyzed 
with MS as exposure. 
 
4.5.2 Statistical methods 
The risk of being diagnosed with an event among exposed individuals was obtained by 
calculating hazard ratios (HR) with 95% CI in a Cox regression model. The clustering effect 
in the sibling analysis was compensated by using robust sandwich estimates. Two-tailed 
probability values were calculated, with values less than 0.05 regarded as significant. Both in 
the comorbidity and the sibling analyses, we adjusted for immigration status (born in or born 
outside of Sweden); Effect modification was tested by including interaction terms between 
sex and exposure.  
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5 RESULTS AND COMMENTS 
5.1 STUDY I: MICROSCOPIC PARTICLES IN TWO FRACTIONS OF FRESH 
CEREBROSPINAL FLUID IN TWINS WITH SCHIZOPHRENIA OR BIPOLAR 
DISORDER AND IN HEALTHY CONTROLS 
5.1.1 Results 
Spherical particles averaging from 0.1-8.0 µm were identified in CSF with scanning electron 
microscopy, for example see figure below (Figure 7). Probands, i.e. patients with 
schizophrenia, schizoaffective or bipolar disorder were more likely than healthy controls to 
have structures in the CSF, but also the co-twins were more likely to have CSF-structures 
(Table 2). Psychotropic medication, albumin ratio, BMI, lifetime anxiety syndrome, any 
medical disorder, smoking status and inflammatory markers in serum did not affect the 
results. Lifetime alcohol abuse or dependence was strongly associated with proband status, 
but when we removed the probands with previous or ongoing alcohol misuse (n=7) the 
association between the probands and CSF-structures remained (OR: 131, CI 9.0-999, 
p<0.0001). In the co-twins we found a greater proportion of positive CSF findings in the MZ 
co-twins (57%) than in the DZ co-twins (20%) though the difference was not found to be 
significant (Fisher's Exact Test: F=3, p=0.22). 
 
Group status (n) Positive CSF 
findings (%) 
Odds ratio* 95% CI p-value 
Probands (n=17) 12 (70.6) 48.5 8.2-550.8 < 0.0001 
Co-twins (n=12) 5 (41.7) 16.2 2.0-217.8 0.006 
Healthy controls (n=65) and 
unaffected twins (n=8) 
3 (4.1) Reference - - 
Total (n=102) 20 (19.6)    
 
Table 2. Distribution of scanning electron microscopic findings in cerebrospinal fluid 
(CSF) The proband group includes patients with schizophrenia (n=7), schizoaffective (n=2) 
and bipolar disorder (n=8). CI: Confidence interval. * Conditional logistic regression analysis 
with age and sex as covariates 
 
5.1.2 Comments 
Microscopic structures in the CSF were strongly associated with schizophrenia, 
schizoaffective disorder and bipolar disorder in the twin sample which confirms previous 
reports [103, 104]. The one study performed in Finland in 2003 that did not find any 
association between microscopic structures and schizophrenia analyzed frozen CSF using 
other methodological differences, which may explain the negative findings [105]. Moreover 
structures were found to be more common in the not affected co-twins with a liability for 
schizophrenia, schizoaffective disorder, or bipolar disorder compared with healthy controls. 
This result suggests a genetic influence on the microscopic structures but also an influence 
from common environmental factors. In the MZ co-twins CSF structures were more frequent 
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than in the DZ co-twins, and although not significant, one may speculate that the presence of 
CSF structures is genetically driven. 
The structures were rare in the non-affected controls but a smaller proportion of the controls 
presented positive CSF-findings. For instance, CSF structures were found in patients with 
atrial fibrillation and Parkinson’s disease. Moreover, in a previous case-report CSF-structures 
were found in a patient with amyotrophic lateral sclerosis [141], indicating that other medical 
conditions may affect the presence of structures in the CSF. 
 
 
Figure 7. Scanning electron microscopy pictures of a filter showing the contents of 
cerebrospinal fluid from a twin with schizophrenia. In picture A: Macrophage-like structure 
(magnification x1700) and B: Structures averaging between 1 to 4 µm in size (magnification 
x7000). The non-affected co-twin did not exhibit any similar structures in the cerebrospinal 
fluid. (Photos: Rolf Nybom, unpublished data) 
 
5.2 STUDY II: MICROPARTICLES AND MICROSCOPIC STRUCTURES IN 
THREE FRACTIONS OF FRESH CEREBROSPINAL FLUID IN 
SCHIZOPHRENIA: CASE REPORT OF TWINS. 
5.2.1 Results 
In the CSF of the twin pair with schizophrenia the overall rate of microparticles in CSF was 
higher compared with the controls. Microparticle levels of leukocyte (CD45) and endothelial 
origin (CD144) were observed to be higher than in the controls, whereas the levels of platelet 
origin (CD42a) were lower. In plasma the level of microparticles did not differ between the 
groups. The CSF blood ratio of platelet-derived microparticles was about 1:1000 indicating 
that the blood CSF barrier is dense not allowing an influx of microparticles from blood to the 
CSF. 
CSF fraction I (representing the first 50 µl of CSF) may reflect the composition of the lumbar 
dural sac; CSF fraction II (representing the next 7 ml of CSF) may reflect the more rostral 
spinal fluid, and CSF fraction III (representing the next 14 ml of CSF) may possibly reflect 
the contents of ventricular CSF [142]. A possible gradient was seen between CSF fraction I 
and II in both twins while the microparticle levels in fraction III were clearly elevated in one 
of the twins but not in the other (Table 3). Three fractions of CSF were investigated with the 
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scanning electron microscopy technique in the twins with schizophrenia. The result from this 
examination was compared with a similar examination carried out three years earlier: a 
similar microscopic pattern was seen between the two examinations (Table 3). 
 
 
CSF or 
plasma 
fraction 
a
 
PS-MP CD42a CD144 CD45 
SEM 
structures
 b
 
Twin 1 
I 94 4 17 25 Many 
II 71 0 19 17 Many 
III 79 1 19 24 Many 
Plasma 11699 8388 806 2013 - 
Twin 2 
I 116 3 27 32 Many 
II 83 2 24 19 Many 
III 334 15 77 137 Many 
Plasma 19492 14356 864 2920 - 
Controls n=4 
c
 
I 32
 
9 2 6 None 
II 31 8 1 7 None 
Plasma 13298 11402 601 2044 - 
 
Table 3 Microparticles in three fractions of cerebrospinal fluid (CSF), plasma and results 
from the scanning electron microscopic examination (SEM structures) in two fractions of 
CSF. The results in CSF fraction I, II and III are presented as number of MP events in the 
microparticle gate during 45 seconds of measurement and in plasma as absolute numbers of 
microparticles (10
6
/l) 
 
PS-MP: Phosphatidylserine activated MPs, CD42a: Platelet derived MPs, CD45: Leukocyte derived MPs, 
CD144-CSF: Endothelial derived MPs. a) CSF I: first CSF-drops (approximately 50 µl) sampled at lumbar 
puncture, CSF II after sampling of >7 mL and CSF III after sampling of >14 mL. b) Twin 1 and Twin 2 both 
displayed “Many” structures in CSF fraction I and II in the CSF-examination three years earlier. c) Presented 
as mean values of the results from the four controls 
 
5.2.2 Comments 
This is a case-report with interesting but possible spurious findings. Increased CSF levels of 
microparticles of leucocyte and endothelial, but not of platelet origin were found in patients 
with schizophrenia. In CSF a higher frequency of microparticles of leucocyte and endothelial 
origin may be an indicator of activation of those particular cell types (e.g., because of an 
ongoing inflammation, increased stress or apoptosis). Another possibility may be a worsened 
clearance process of the CSF. Although, disturbances of the CSF clearance processes as the 
only explanation would be less likely because increased levels of microparticles of platelet 
origin would then be expected as well. Thus, cell activation or an increase of the cell-decay 
would be more probable explanations that may reflect an increased stress exposure at the cell 
level. If it depends on schizophrenia or other factors such as antipsychotic medication 
remains to be determined. A disturbance of the endothelial and leucocyte function may be a 
target for future schizophrenia research. 
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5.3 STUDY III: CEREBROSPINAL FLUID MICROGLIA AND AMYLOID 
BIOMARKERS IN TWINS CONCORDANT OR DISCORDANT FOR 
PSYCHOTIC DISORDERS 
5.3.1 Results 
The correlations of the biomarker levels within all twin-pairs (n=17) were estimated, with 
significant high correlations (r>0.7) being found in the MZ twin pairs of the biomarkers 
sCD14, YKL-40, Aβ-38, Aβ-40, sAPP-α, sAPP-β, T-tau, and P-tau. The correlation of 
sCD14 was especially high in the MZ twins (r=0.96, p<0.0001) but was also significant in the 
DZ twin pairs (r=0.73, p=0.028) (Figure 8A). No significant correlations were seen in the MZ 
twin pairs of MCP-1, Aβ-42, Aβ-1-42 and the albumin ratio. No other significant correlations 
were observed in the DZ pairs except for sCD14. 
The co-twin control analysis of the MZ and DZ pairs discordant for schizophrenia or bipolar 
disorder (n=11) showed elevated levels of sCD14 in the probands compared with their non-
affected co-twins (Figure 8B). When stratified by zygosity no general significant differences 
were noted within the MZ and DZ twins. 
 
 
Figure 8 A: Scatterplot of the within twin pair correlations of sCD14 in the monozygotic 
(MZ) and the dizygotic (DZ) pairs (n=17). B: Profile plot of the within twin pair analysis of 
the disease discordant pairs (n=11) where each line illustrates the difference in sCD14 
concentration between the proband and its co-twin. 
 
We also analyzed the CSF biomarker levels in relation to psychometric assessment scales for 
psychosis: SANS, SAPS, SPQ-B and SCID-II screening (cluster A section). We found 
significant associations between sCD14 and the SANS scale measuring negative psychotic 
symptoms and the cluster A section of the SCID-II screening scale measuring paranoid, 
schizoid and schizotypal personality traits. 
When we analyzed the influence of potential confounders on the biomarker levels, a strong 
association was detected between the albumin ratio and sCD14 [Estimate 0.5, 95% 
Confidence Interval (CI) 0.3-0.7, p<0.0001]. Increased albumin ratio levels indicate a 
disturbed function of the blood-CSF-barrier function. To further explore the relationship 
between sCD14 and the albumin ratio correlations of the intra-pair differences of sCD14 and 
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the albumin ratio were compared in the MZ and DZ twin pairs. The correlations were higher 
in the DZ pairs (r=0.81, p=0.015) compared with the MZ pairs (r=0.10, p=0.80) (Figure 9). 
Finally, we analyzed associations between CSF biomarker levels and presence of microscopic 
particles presented in Study I. No significant associations were seen between microscopic 
particles and any of the CSF biomarkers. 
 
 
Figure 9. The intra-pair differences of the albumin ratio and sCD14 in the monozygotic 
and dizygotic twin pairs. 
 
5.3.2 Comments 
The high correlations within the MZ twin pairs of the immune markers (sCD14 and YKL-
40), the amyloid proteins (Aβ-38, Aβ-40, sAPPα, sAPPβ) and the tau-proteins (t-tau, and p-
tau) in CSF may indicate a substantial genetic influence. In the DZ twins a significant 
correlation was found of sCD14 only, but because of the wide CI it was not possible to 
exclude additional influences from a shared environment. By contrast, no significant 
correlations were found in the MZ or DZ twins for the amyloid proteins Aβ-42, Aβ-1-42, the 
chemokine MCP-1/CCL2, and the albumin ratio, indicating a lower degree of genetic 
influence. 
 
In the co-twin control analysis elevated levels of sCD14 were found in the twins affected by 
psychotic disorders compared with their co-twins. This result precludes an effect due to a 
shared environment. Yet, no significant differences between proband and co-twin were seen 
in the MZ twin pairs alone and thus it was not possible to rule out genetic influences on the 
higher sCD14 levels in the patients. When analyzing the discordant twin pairs for 
schizophrenia, significant higher levels of sCD14 were seen using the paired t-test, but not in 
the bipolar twin pairs. This finding may together with the positive associations found between 
sCD14 and scales measuring negative psychotic symptoms and the SCID-II screening 
indicate that increased CSF sCD14 levels may be associated with psychosis. 
 
An association between sCD14 and the albumin ratio has been reported in bipolar patients 
and healthy controls [85] and associations between elevated albumin ratio-levels (as an 
indicator of blood-CSF-barrier dysfunction) and psychotic disorders have also been found 
[75]. In this study the albumin ratio was significantly elevated in patients with schizophrenia 
and bipolar disorder compared with their non-affected co-twins. One explanation for the 
sCD14 elevation may be a consequence of a CSF barrier dysfunction (e.g., that increased 
 - 30 - 
 
CSF sCD14 levels are caused by an influx of sCD14 from peripheral blood because of a 
general inflammatory process). Nevertheless, the study by Jakobsson and co-workers did not 
find any correlation between serum and CSF sCD14 levels in bipolar patients, which may 
speak against an influx of sCD14 from blood to CSF [85]. In the current study the correlation 
of the intra-pair differences of albumin ratio and sCD14 were higher in the DZ twins 
compared with the MZ twins (Figure 9). This result indicate that genetic confounding may 
play a role in the association between sCD14 and the albumin ratio which may not be in 
agreement with the explanation model of sCD14 influx from peripheral (Figure 9). 
 
Thus, higher CSF sCD14 levels in schizophrenia and bipolar disorder may be due to an 
increased production by the macrophages of the CNS, microglia. The MZ intra-pair 
correlations indicate that regulation of the sCD14-levels is highly genetic. The CD14 gene is 
located on chromosome 5 and previous GWAS analyses have found associations between 
single nucleotide polymorphisms in the region and cardiovascular disease [81]. Yet, the 
GWAS study by the Psychiatric Genetic Consortium in 2013 [143] only found a single 
nucleotide polymorphisms association (chr5_140143664) approximately 150 base pairs away 
from the CD14 gene which is probably too far to be associated with the CD14 gene. Thus the 
functions and mechanisms underlying sCD14 remain elusive. 
 
 
Biomarkers 
Spearman’s 
correlation 
coefficient 
p-value 
Aβ-42 and Aβ-1-42 r=0.94 p<0.0001 
Aβ-40 and Aβ-1-42 r=0.94 p<0.0001 
Total tau and P-tau r=0.93 p<0.0001 
Aβ-38 and Aβ-40  r=0.92 p<0.0001 
sAPP-α and sAPP-β r=0.92 p<0.0001 
Aβ-38 and Aβ-42 r=0.91  p<0.0001 
Aβ-40 and Aβ-42 r=0.90  p<0.0001 
Aβ-38 and Aβ-1-42 r=0.85  p<0.0001 
sAPP-beta and AB-40 r=0.71  p<0.0015 
 
Table 4. Intra-pair correlations of all twin pairs (n=17) between biomarkers in which 
Spearman’s coefficient was >0.7. Aβ=Amyloid-β, P-tau= Phosphorylated tau, sAPP=soluble Amyloid 
Precursor Protein. 
 
When several biomarkers are tested simultaneously the problem of multiple testing arises. As 
we analyzed in total 12 different biomarkers including the albumin ratio and the significance 
level was set at α 0.05, then after Bonferroni correction we would arrive at a reference p-
value of 0.0042 [144]. This means that none of the results from the co-twin control analysis 
would reach the significance level. But, several of the biomarkers are highly correlated within 
groups and this applies to the amyloid peptides (Aβ-38, Aβ-40, Aβ-42, Aβ-1-42), the tau-
proteins (T-tau and P-tau) and sAPP-α and β (Table 4). If the amyloid peptides, the tau-
proteins and the sAPPs are accounted for as three separate groups (instead of eight different 
biomarkers) then the reference p-value according to Bonferroni would arrive at 0.0071. This 
suggests that the significant results of the co-twin control analysis of sCD14 would remain 
significant. 
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5.4 STUDY IV: ASSOCIATION BETWEEN KYNURENIC ACID AND 
SCHIZOTYPAL PERSONALITY TRAITS IN TWIN PAIRS WITH 
PSYCHIATRIC MORBIDITY 
5.4.1 Results 
No differences for any of the tryptophan metabolites were found when comparing the 
probands and the co-twins. Nor were any significant within twin pair correlations found in the 
MZ pairs. The tryptophan metabolite results were analyzed against the results from the 
assessment scales measuring schizotypal and psychotic symptoms. Significant associations 
were found between kynurenic acid and the total scores of the SPQ-B and SCID-II (cluster 
A). A significant association was also found between quinolinic acid and the SPQ-B score 
(Table 5). No other kynurenines or cytokines were associated to any of the rating scales. 
Further analyses of the subscales within Cluster A revealed that kynurenic acid was 
associated to the subscale of schizotypal personality traits (p=0.013) and showed a trend 
towards significance of the paranoid subscale (p=0.062). No-significant results were found 
for the subscale of schizoid personality traits (p=0.103). 
 
 
SPQ-B 
Estimate (95%CI) 
P 
SCID-II 
Estimate (95%CI) 
P Co-factor 
Kynurenic acid (nM) 1.048 (1.000-1.099) 0.049 1.082(1.015-1.153) 0.018 Smoking 
Quinolinic acid (nM) 1.051 (1.006-1.098) 0.027 1.001 (0.928-1.079) 0.982 CSF Albumin 
Tryptophan (M) 1.007 (0.980-1.034) 0.606 1.008 (0.978-1.039) 0.588 None 
IL-6 (pg/ml) 0.977 (0.925-1.031) 0.377 0.994 (0.925-1.070) 0.872 Snuff 
IL-8 (pg/ml) 0.979 (0.956-1.002) 0.067 0.983 (0.956-1.011) 0.193 Neuroleptic 
TNF- (pg/ml) 0.985 (0.966-1.005) 0.127 0.985 (0.959-1.012) 0.241 Neuroleptic 
 
 SANS 
Estimate (95%CI) 
P SAPS 
Estimate (95%CI) 
P Co-factor 
Kynurenic acid (nM) 1.010 (0.998-1.023) 0.562 1.019 (0.998-1.042) 0.075 Smoking 
Qunolinic acid (nM) 1.008 (0.995-1.021) 0.223 1.004 (0.984-1.025) 0.647 CSF Albumin 
Tryptophan (M) 0.997 (0.991-1.003) 0.346 0.996 (0.984-1.007) 0.455 None 
IL-6 (pg/ml) 0.998 (0.984-1.012) 0.734 1.001 (0.986-1.015) 0.935 Snuff 
IL-8 (pg/ml) 0.994 (0.986-1.003) 0.187 0.999 (0.987-1.012) 0.867 Neuroleptic 
TNF- (pg/ml) 0.996 (0.989-1.003) 0.278 0.992 (0.983-1.000) 0.057 Neuroleptic 
Table 5. Association between tryptophan metabolites, cytokines and results from the 
psychometric assessment scales. IL=Interleukin, TNF=Tumor necrosis factor 
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5.4.2 Comments 
Associations were found between kynurenic acid, quinolinic acid and schizotypal personality 
traits. Several studies have shown that schizotypal personality disorder symptoms are higher 
in patients with schizophrenia and their relatives than they are in the general population [145] 
and that SPQ-B total scores are stable over time in patients with schizophrenia and their 
relatives [146]. The association between kynurenic acid and the schizotypal traits in the 
SCID-II scale is also in line with these results. The result reinforces previous findings of an 
association between psychosis and an imbalance in the kynurenine metabolites of the 
tryptophan pathway. The within twin pair analyses did not show any significant differences 
and because of the small sample size it is risky to comment on potential genetic and 
environmental effects. The lack of correlations within the MZ twin pairs of all biomarkers 
investigated suggests that environmental factors have a greater influence on the tryptophan 
metabolites and the interleukins (Il-6 and Il-8) rather than genetic factors. 
 
5.5 STUDY V: MULTIPLE SCLEROSIS AND PSYCHIATRIC DISORDERS: 
COMORBIDITY AND SIBLING RISK IN A NATIONWIDE SWEDISH 
COHORT 
5.5.1 Results 
Increased risk of MS was found in bipolar disorder, including bipolar disorder type I, and 
depression, but patients with schizophrenia were less likely to develop MS as shown in figure 
(Figure 10). No differences were seen in the mixed category. No differences were detected in 
the depression group when using one or two hospital admissions as criteria for depression. 
Corresponding results were seen in the reversed analysis assessing the risk of psychiatric 
disorders in patients affected by MS. No significant differences in MS risk were found in the 
siblings to patients with schizophrenia, bipolar disorder and depression. Similar results were 
seen when analyzing the data in the opposite direction. 
In the comorbidity cohort the analysis was stratified by sex, which showed an increased risk 
of MS in males with bipolar type I compared to females (Figure 11). No temporal association 
was found between MS risk and date of onset of the psychiatric disorder, and conversely no 
temporal association was found between the risk of a psychiatric disorder and date of onset of 
MS. 
 
5.5.2 Comments 
As in previous studies, the risk of MS was increased in patients with bipolar disorder and 
depression. One possible explanation for these findings includes the psychological burden of 
being diagnosed with MS, which could increase the risk of depression. Another explanation 
is that MS-medications such as steroids and interferons trigger affective mood-swings that 
increase the probability of being diagnosed with depression or bipolar disorder in the MS 
patients. A temporal association could not be found, however, between MS and bipolar 
disorder and depression. For instance there were not any differences in the depression risk 
nearby the first MS diagnosis, compared to more than two years before or two years after the 
MS-onset. Instead the risk pattern was spread out over time and one possible explanation to 
this pattern may be that the CNS inflammation in MS decreases the threshold in the brain to 
be affected by changes in the mood as in depression or bipolar disorder. This increased 
susceptibility may start years before the patient is diagnosed with MS. Given the differences 
 - 33 - 
 
between males and females, it is also possible that, for instance sex-hormones affect the risk 
in that estrogen has been found to be neuroprotective in animal models of MS [147]. 
The decreased MS risk in patients with schizophrenia was not seen in the siblings to the 
patients with schizophrenia. Nevertheless, in a large GWAS study carried out on patients with 
MS (n=27,148), schizophrenia (n=21,856) and bipolar disorder (n=16,731) MS risk alleles in 
the human leukocyte antigen complex were associated with a decreased risk of schizophrenia 
[148]. Further analysis showed that the alleles DRB1*03:01 and DQB1*02:01, reported to 
increase the risk of MS, decreased the risk of schizophrenia while no genetic overlap was 
found between MS and bipolar disorder. These results indicate that the sibling comparison in 
this study may not reveal certain genetic associations or that the size of the population 
analyzed in this study was not large enough. 
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Figure 11. Risk of MS in various psychiatric disorders stratified by sex. In comparison with 
females, MS risk was clearly increased in males with bipolar disorder and an episode of 
mania with psychosis (Bipolar type I). 
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6 GENERAL DISCUSSION 
6.1 CONCLUSIONS 
Study I 
 Microscopic structures were common in the CSF of twins with schizophrenia and 
bipolar disorder and were more frequent in their non-affected co-twins. This finding 
indicates that the precense of structures may be due to genetic or shared 
environmental factors. 
 CSF structures were very unusual in healthy individuals, indicating that the structures 
are not likely to be found randomly in the healthy population. 
 The structures in the CSF were also seen in patients with somatic disorders (e.g., 
instance Parkinson’s disease) and may not be spcecific to psychiatric disorders. 
Study II 
 The CSF structures were stable over time according to a case-series study. 
 In patients with schizophrenia microparticles (microvesicles) of leucocyte and 
endothelial origin were elevated, which may reflect raised immune activation. 
Study III 
 Several immune- and amyloid biomarkers were highly correlated within MZ twin 
pairs, suggesting that hereditary factors are of importance for its baseline levels. 
 The biomarkers MCP-1, Aβ-42, Aβ-1-42 and the albumin ratio were not correlated in 
the MZ twins, indicating a higher degree of environmental influence. 
 sCD14 was increased in twins with psychotic disorders as compared with their co-
twins, indicating that disease-related factors may give rise to the elevated levels in 
addition to genetic factors. 
 Higher levels of sCD14 were associated with a higher degree of negative psychotic 
symptoms and paranoid and schizotypal personality traits. This observation is in 
accordence with previous findings of elevated sCD14 levels in patients with 
schizophrenia and bipolar disorder. 
Study IV 
 Associations were found between higher degrees of schizotypal traits and increased 
levels of kynurenic acid and quinolinic acid. 
 No significant correlations of any of the tryptophan metabolites or cytokines were 
found within the MZ twin pairs – indicating that environmental factors may be of 
importance for the biomarker levels in the tryptophan pathway. 
 No changes in biomarker levels were seen when comparing the probands with the co-
twins. 
 An important limitation of this study was the limited sample of twins could lead to 
false negative results. 
Study V 
 A diagnosis of bipolar disorder or depression increased the risk of being affected by 
MS; conversly MS increases the risk of bipolar disorder and depression. 
 Males with bipolar disorder type I had a greater risk of being affected by MS than 
females suggesting that sex-specific differences may impact disease liability. 
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 Schizophrenia patients had a decreased risk of being affected with MS, and conversly, 
MS decreased the risk of schizophrenia. This protective effect between schizophrenia 
and MS may partly be explained by pleiotrophic mechansims in the genome. 
 No change in the risk of MS was found in siblings to patients with schizophrenia, 
bipolar disorder or depression. Conversly no increased psychopathology was seen in 
siblings to patients with MS. These findings indicate that there is no general 
genetically determined liability that cuases the observed comorbidities. 
 There was no temporal association between the onset of MS and bipolar disorder, 
reducing the likelihood that the comorbidity is due to an effect of medication alone or 
a psychologically driven reaction by the time of disease onset. 
 
6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Strengths 
The population-based recruitment of twins in Study I-IV is a general strength of this thesis, 
along with the detailed diagnostic characterization combined with information on hospital 
admissions over lifetime. Moreover, a thorough collection of demographic data and the 
measurement of symptoms using various assessment scales enabled us to integrate data from 
different domains. Because of the comprehensiveness of the Swedish registers, we were able 
to analyze in Study V comorbidities and sibling risks in the largest population-based study so 
far performed in our field of interest. 
6.2.2 Small samples and twin designs 
In Study I-IV potential CSF biomarkers of schizophrenia and bipolar disorder were studied in 
twins. By using a twin 
design, it is possible to 
disentangle genetic and 
environmental influences on 
a certain trait. However, it is 
a demanding task to collect 
enough CSF samples to 
reach sufficient power in the 
analysis. Twin pairs 
concordant or discordant for 
schizophrenia or bipolar 
disorder are rare and lumbar 
puncture is a troublesome 
procedure to endure as a 
study participant. In the 
recruitment procedure it is 
not unusual that the 
participant refuses to 
participate.  
When using a small sample 
the risk of random errors is 
high and thus the precision is 
reduced. In Study I we tested 
the hypothesis that a positive 
Testing the “Null hypothesis” 
 
When performing an experiment, you set up a “null 
hypothesis”, which usually means that there is no difference 
between the groups that you want to compare, and an 
“alternative hypothesis”, which implies that the groups differ 
from each other. After a statistical test, you may reject the “null 
hypothesis” if you find a difference between the comparison 
groups. However, there is still a chance that the “null 
hypothesis” in reality is true; if so, the mistake that you make is 
called a “Type I error”. Alternatively, you may not be able to 
reject the “null hypothesis”. Then if the “alternative hypothesis” 
in reality is true, the mistake is called a “Type II error”. 
 
 
"Null hypothesis" 
is true 
"Alternative 
hypothesis" is true 
Study result: 
"Null hypothesis" 
accepted 
True null finding 
Type II error (False 
negative result) 
Study result: 
"Alternative 
hypothesis" 
accepted 
Type I error (False 
positive result) 
True finding 
 
Table that summarizes the possible outcomes of hypothesis-
testing  
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finding of CSF structures would increase the risk of psychosis or the heritability of psychosis. 
Before performing the analysis, a significance level of 0.05 was set. Thus, a p-value less than 
0.05 implies that the results are inconsistent with the null hypothesis. To indicate precision of 
an estimate we use CIs and they are typically stated at 95% confidence level. It means that if 
the data were replicated many times, the true value should be within the CI 95% of the time. 
The CIs of the main results in Study I were wide, indicating a low precision of the results. A 
replication of the findings in a larger sample would increase the precision. 
Systematic errors such as selection bias are a potential problem in our sample. Of the twins 
participating in the STAR study, only a small number (approximately 15% of the disease 
discordant pairs) agreed to participate in the CSF study. Selection bias may have arisen if 
those who agreed to participate in the CSF study differentiate from the whole twin population 
in a systematic way that we are not aware of. If that were the case, our results may not be 
generalizable to the population. Moreover, information bias may have arisen (e.g., by 
misclassification of the microscopic findings) in Study I and II during the scanning electron 
microscope investigation procedure. A way to overcome this problem is to have the gold-
coated filters with CSF blindly re-examined by another independent researcher in the future.  
Several biomarkers were analyzed simultaneously, in Study III and IV, which may introduce 
the problem of multiple comparisons. When the significance level is set at α 0.05, provided 
that the null hypothesis is true, the chance of a false positive result (Type I error) will be 1 out 
of 20. This result may be corrected for statistically by using the Bonferroni correction [144]. 
But the Bonferroni method is conservative and may instead increase the risk of false 
negatives (Type II error). 
 
6.2.3 Large population-based samples 
In Study V we used a matched cohort design in a large population-based sample. Using large 
sample sizes lowers the risk of random errors. This is because as random errors arise by 
chance, they can be corrected by increasing the sample size. Instead, systematic errors may 
arise if the measurements deviate from the true value in a systematic way. Three types of 
systematic bias are selection bias, information bias and confounding. 
Selection bias occurs when the selection of participants is influenced by factors that may 
cause inaccurate results. For instance, we demanded two hospitalizations to be classified as 
schizophrenia, bipolar disorder or depression and therefore the less severe cases are at risk of 
not being included. We would miss, for example, the patients who were hospitalized only 
once and were followed-up in the out-patient department. This is because in the registers the 
out-patient clinics were included as late as 2001. The risk of selection bias applies especially 
to the depressive patients because most mild cases of depression are treated by family doctors 
and the diagnoses are not visible in the patient register. The decreased risk of MS in patients 
with schizophrenia could also be a result of ascertainment bias, which is a type of selection 
bias. As an example, if patients with schizophrenia have a tendency to be too disabled to seek 
health care when affected by neurological symptoms, the diagnosis of MS may go undetected 
in this patient group. 
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Information bias may result 
from measurement errors 
or misclassification. An 
example of 
misclassification bias in 
Study V is the risk of 
classifying schizophrenia 
as bipolar disorder, or 
conversely classifying 
bipolar disorder as 
schizophrenia. The risk of 
being affected by MS in 
schizophrenia and bipolar 
disorder has been shown to 
occur in the opposite 
directions. Too many 
misclassifications of 
schizophrenia and bipolar 
disorder would 
hypothetically lead to a null 
result. To overcome this 
problem we separated the 
groups of bipolar and 
schizophrenia patients 
carefully by not allowing 
any diagnostic overlap. 
This resulted in a larger 
group of unclear cases 
(n=15,776), with a mixture 
of schizophrenia, 
schizoaffective and bipolar diagnosis. Figure 12 depicts the number of patients with 
schizophrenia, schizoaffective and bipolar diagnosis. 
Another potential source of bias was the lack of a validation study of the depression 
diagnoses in the National Patient Register. High validity of a measurement means that it 
measures what it is supposed to measure. Thus, in our study there is an uncertainty regarding 
the depressive patients. The use of two discharge diagnoses for depression makes the 
specificity higher and decreases the risk of including false positive cases in the study; 
however, it may instead result in missed cases, i.e. lower sensitivity. On the other hand 
according to Figure 10 there were no significant differences in the risk of MS when applying 
the criteria of one hospitalization for depression compared with two hospitalizations. 
Nevertheless, with respect to depression, there is a risk that the results in Study 5 are 
underestimated in particular what regards to milder cases of depression that are more often 
diagnosed at Family doctors that are not providing data to the National Patient Register. 
Confounding is a confusing of effects and is a form of systematic error. It must be associated 
with the disease and the exposure but must not be an effect of the exposure [149]. In Study V 
we used matching as a method to overcome the confounding effects of age and sex. We also 
selected the controls randomly. Still, we were not able to control for a number of known and 
unknown confounders (e.g., we did not have access to data on smoking status, which is a 
well-known risk factor for MS).  
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7 ETHICAL CONSIDERATIONS 
All studies in this thesis were approved by the Regional Ethical Review Board in Stockholm. 
The studies were performed according to the Helsinki Declaration. In Study I-IV all enrolled 
patients and controls consented orally and in writing to participate in the study. 
In Studies I-IV the study participants agreed to take part in a lumbar puncture as well as a 
blood sampling procedure. Lumbar puncture may result in side-effects, in which headache is 
the most common and may in some cases be very troublesome for the affected. Therefore, it 
is of importance that the potential risks the study participants are exposed to are balanced 
against the utility of the research performed. Schizophrenia and bipolar disorder are severe 
disorders causing a major distress for the affected individuals and their families. In this case 
the benefits of learning more about schizophrenia and bipolar disorder and ultimately 
providing a better life for these individuals outweigh the disadvantages. In Study V no 
interventions were made on the study participants and all the data used for the analyses were 
collected through the Swedish healthcare system and other population based registers in 
Sweden. 
In Figure 2 (page 8) in the thesis summary a picture of a filter from a scanning electron 
microscopy examination is presented as an example. The CSF on the filter is from a patient 
included in another study that was approved by the ethical committee of the University of 
Umeå (#99-191).  
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8 THESIS IMPLICATIONS AND FUTURE RESEARCH 
8.1 MICROSCOPIC STRUCTURES – A TRAIT MARKER OF PSYCHOSIS 
In Study I we were able to replicate previous findings from bipolar and schizophrenia patients 
and found associations between micrometer-sized CSF structures and schizophrenia and 
bipolar disorder. We also observed an increased frequency of CSF structures in the non-
affected twin siblings of the patients with psychosis. In Study II we found that the presence of 
CSF structures was stable over 3 years. In Study III we analyzed the relationship between 
CSF structures and immune and amyloid biomarkers but did not detect any associations. 
The structures are very frequent, especially in the patients with schizophrenia and 
schizoaffective disorder where 8 out of 9 patients had a positive finding of CSF structures; on 
the other hand, the CSF structures were very rare in the healthy controls. Moreover, the 
structures seem to be stable over time and are more frequent in individuals with a 
susceptibility to schizophrenia and bipolar disorder. Even if our data indicate that the 
structures found in CSF may be potential biomarker candidates, the CSF structures are not 
yet suitable as biomarkers for several reasons. First, we found indications that similar 
structures occur in patients with other CNS disorders (e.g., Parkinson’s disease and 
amyotrophic lateral sclerosis) [141] and may also be due to atrial fibrillation, i.e. they are not 
specific to psychotic disorders. Second, the technique to identify CSF structures depends on 
the assessment of a human and currently a safe technique to quantify the structures is lacking. 
Third, the scanning electron microscope technique is resource demanding and thus 
investigating larger samples is not feasible. Fourth, we have too little knowledge of the 
changes over time of the structures: for instance, we don’t know if structures exist in the 
prodromal phase of psychosis. Finally, we don’t know what the structures are composed of, 
how they are formed within the CSF and which role they play in the disease process. 
Future research requires replications of the microscopic findings in other research groups 
using the same procedures. Standardizations of the measurements are essential to be able to 
evaluate and quantify the structures. Further studies are required where the microscopic 
findings are related to other measurements such as neuro-imaging data and 
neuropsychological testing. 
 
8.2 NEUROINFLAMMATION AND THE TRYPTOPHAN METABOLISM – A 
COMPLEX NETWORK 
In Study III and IV substances and metabolites linked to inflammation and the tryptophan 
metabolism were analyzed in a twin model. A growing number of studies in recent years have 
shown linkage of CNS disorders to neuroinflammatory processes and abnormalities in the 
tryptophan metabolism. In this thesis we found that elevated CSF sCD14 levels in 
schizophrenia and bipolar patients could be driven by disease-specific factors in combination 
with a genetic predisposition, although the limited number of twins in the analysis makes the 
conclusions premature. The associations between psychotic symptoms and higher CSF levels 
of sCD14, kynurenic acid and quinolinic acid strengthen previous findings of associations 
between psychosis and the biomarkers. 
In the immune system a large number of signaling substances, metabolites and cells interact 
in a complex network that may be hard to overview. Single inflammatory markers may not be 
suitable as biomarkers alone because they are not specific to psychiatric disorders. One 
approach to overcome this problem would be to investigate a battery of biochemical markers 
alone or in combination with genetic, cognitive or neuroimaging biomarkers to determine 
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predictors of psychiatric disorders or symptoms in the complicated network of biochemical 
processes. The use of network analysis has shown to be promising even in smaller CSF 
samples in order to find pathways of significance [150]; however, larger sample sizes are 
essential to gain better precision in the analysis. sCD14 is increased in acute as well as 
chronic diseases and considering the high correlation of sCD14 in MZ twins, further analysis 
of the genetic properties would be one way to further explore its significance. In Study II, 
microparticles were analyzed for the first time in schizophrenia and the result showing 
microparticles of leucocyte and endothelial origin may be in agreement with the findings in 
Study III of an ongoing inflammatory process. Future studies on CSF in schizophrenia 
patients are desirable. 
 
8.3 PSYCHIATRIC DISORDERS AND MULTIPLE SCLEROSIS – WHAT CAN 
WE LEARN? 
On the surface, Study V does not seem to be related to the first four studies of this thesis. To 
achieve a better understanding of the mechanisms underlying a disease it is important to 
explore possible links between different illnesses in larger populations. Similar to 
schizophrenia and bipolar disorder, MS is an inflammatory disorder of the CNS. Through 
investigation of the comorbidity and sibling risk in relation to psychiatric disorders, 
hereditary and environmental relationships may be explored. 
The interpretation of the co-occurrence of MS and bipolar disorder and depression indicates 
that neuroinflammation increases the risk for comorbidity of MS, as well as bipolar disorder 
and depression. A future study design would be to analyze whether the exposure for 
medications used for bipolar disorder (i.e. lithium), depression (i.e. antidepressants) or MS 
(i.e. interferon-γ or corticosteroids) would affect the prognosis and symptoms of the co-
occurring disorder in comorbid cases. Further, the apparent protective effect of schizophrenia 
on MS is of major interest. The recent discovery of a pleiotropy in an immune-related locus 
that may explain this protective effect requires further investigation (e.g., by looking more 
closely at the actual gene and its products) [148]. A further possibility would be to 
characterize patients with schizophrenia and MS in combination. Differences in the risk of 
MS between males and females with bipolar disorder and an episode of mania should be of 
interest. Finally, possible androgen effects in relation the risk of MS in men and women need 
to be explored. 
 
8.4 FUTURE BIOMARKER CHALLENGES 
The development of biomarkers for psychiatric disorders is highly desirable. We believe that 
clinically useful biomarkers would improve psychiatric health care dramatically. Research in 
this area is intense and it is possible that biomarkers for clinical psychiatry will be available 
in the near future. It is also very likely that future progress within the field will change the 
psychiatric nomenclature, implying some major changes as well as minor adjustments. 
A vision of the future for the clinician would be to have access to a combined battery of 
biomarkers from polygenic risk scores generated from GWAS, through laboratory tests, brain 
imaging investigations down to results from neuropsychological testing batteries and 
symptoms and signs presented by the patient. This thesis involves just a tiny part of an 
enormous puzzle involving many researchers throughout the world. It is our hope that every 
piece of information will be relevant.  
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9 APPENDIX 
 
Appendix table. Descriptive data of all 37 twins of the CSF-cohort 
Note: The twin numbers in the first column have been anonymized and are not comparable to the twin numbers 
of the supplement table of Study 1 (Table S1). 
 
Twin Zygosity Sex Diagnosis 
Age 
of 
onset 
Type of twin 
pair 
Somatic disorder 
Anti- 
psychotic 
medicine
** 
1A MZ Female Schizophrenia 25 Concordant Urinary calculus Yes 
1B MZ Female Schizophrenia 18 Concordant None Yes 
2A MZ Male Schizophrenia 19 Concordant None No 
2B MZ Male Bipolar I 18 Concordant None No 
3A MZ Female Bipolar I 16 Discordant None Yes 
3B MZ Female None . Discordant Vaginal bleeding No 
4A MZ Female Schizophrenia 18 Discordant Diabetes, Hypothyroidism Yes 
4B MZ Female None   Discordant Diabetes, Atrial fibrillation No 
5A* MZ Male Depression 20 Discordant None No 
6A MZ Female Bipolar I 48 Discordant Pain in shoulders No 
6B MZ Female Depression 34 Discordant Headache, Gastritis No 
7A MZ Female Bipolar II 23 Discordant Arthrosis No 
7B MZ Female None . Discordant None No 
8A MZ Male Bipolar I 29 Discordant Diabetes No 
8B MZ Male None   Discordant None No 
9A MZ Male Depression 16 Discordant None No 
9B MZ Male Schizoaffective 16 Discordant None Yes 
10A MZ Male Depression 44 Control twin None No 
10B MZ Male None . Control twin Chronic back pain No 
11A MZ Male Depression 55 Control twin Parkinson, Atrial fibrillation No 
11B MZ Male Depression 51 Control twin Atrial fibrillation No 
12A DZ Male Schizophrenia 28 Concordant None No 
12B DZ Male Schizophrenia 31 Concordant Visual disability Yes 
13A DZ Male None . Discordant None No 
13B DZ Male Schizoaffective 27 Discordant Heart disease Yes 
14A DZ Female Bipolar II 19 Discordant Overweight Yes 
14B DZ Female Depression 29 Discordant Tietze’s syndrome No 
15A DZ Female Depression 54 Discordant None No 
15B DZ Female Bipolar I 43 Discordant None No 
16A DZ Female None . Discordant Malignant melanoma op. No 
16B DZ Female Bipolar II 34 Discordant None No 
17A DZ Female None . Discordant None No 
17B DZ Female Schizophrenia . Discordant None Yes 
18A DZ Male Depression 27 Control twin None No 
18B DZ Male None . Control twin Previous stroke No 
19A DZ Male None . Control twin None No 
19B DZ Male None . Control twin Slipped disc, Chronic pain No 
 
*The other twin in the pair declined participation 
** Antipsychotic medication defined as taken daily.  
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